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and cerebral vessels was related to the severity of cogni-
tive impairment in patients with cerebrovascular disease 
[13]. Also, ALEs have been reported as useful biomarkers 
of oxidative damage. The Michael adduct of HNE to pro-
teins was found to be signiﬁ cantly elevated in patients with 
a variety of oxidative stress-based diseases, such as Alzheim-
er ’ s disease [14], chronic pancreatitis [15], obesity and insu-
lin resistance [16], and systemic lupus erythematosus [17]. 
 Besides being considered as reliable biomarkers of 
oxidative damage, as well as as predictors and prognos-
tic factors, more recently, AGEs and ALEs have also 
been recognized as important pathogenetic factors of 
some oxidative-based diseases, as supported by the fol-
lowing facts: (1) as pointed out above, a strict correlation 
between the amount of AGEs/ALEs in tissues and ﬂ uids 
and disease states has been found, in both animal and 
human subjects; (2) a substantial amount of literature is 
now available reporting the molecular and cellular patho-
genic mechanisms for the AGEs/ALEs involvement in 
the onset and progression of diﬀ erent diseases, including 
atherosclerosis, diabetes, and neurological disorders. 
The AGE/ALE damaging eﬀ ect is mediated by diﬀ erent 
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 Abstract 
 The advanced glycoxidation end products (AGEs) and lipoxidation end products (ALEs) contribute to the development of diabetic 
complications and of other pathologies. The review discusses the possibilities of counteracting the formation and stimulating the 
degradation of these species by pharmaceuticals and natural compounds. The review discusses inhibitors of ALE and AGE formation, 
cross-link breakers, ALE/AGE elimination by enzymes and proteolytic systems, receptors for advanced glycation end products (RAGEs) 
and blockade of the ligand – RAGE axis. 
 Keywords:  Glycoxidation ,  lipoxidation ,  antioxidants ,  cross-link breakers ,  proteasomes 
 Abbreviations: A β , amyloid  β -peptide; AD, Alzheimer ’ s disease; AGEs, advanced glycoxidation end products; ALEs, advanced lipoxidation 
end products; CEL, N- ε -(carboxyethyl)lysine; CML, N- ε -(carboxymethyl)lysine; DAP, diaminopropionic acid; 3-DG, 3-deoxyglucosone; 
FN3K, fructosamine-3-kinase; GO, glyoxal; GOLD, glyoxal–lysine dimer; GSH, glutathione; HMGB1, high-mobility group box 1proteins; 
HNE, 4-hydroxynonenal; LDL, low-density lipoprotein; oxLDL, oxidized LDL; LPA, lysophosphatidic acid; MDA, malondialdehyde; 
MG, methylglyoxal; MMP, metalloproteinase; MOLD, methylglyoxal–lysine dimer; ONE, 4-oxo-2-nonenal; PM, pyridoxamine; PTB, 
N-phenacylthiazolium; PMT, pyridinium (3-[[2-(methylsulfonyl) hydrazino] carbonyl]-1-[2-oxo-2-2-thienyl) ethyl]); RAGE, receptor 
for advanced glycation end products; fRAGE, full-length RAGE; sRAGE, shortened RAGE; esRAGE, endogenous secretory RAGE; 
RCS, reactive carbonyl species; ROS, reactive oxygen species; STZ, streptozotocin; UPS, ubiquitin-proteasome system; VEGF, vascular 
endothelial growth factor.  
 AGEs, ALEs, and RAGE as drug target (GA) 
 Advanced glycoxidation [1 – 3] end products (AGEs) and 
advanced lipoxidation end-products (ALEs) are widely 
studied as reporters of oxidative and glycoxidative 
damage [4 – 8]. The most common analytical methods 
for their quantitative determination are based on 
ELISA or Western blot assays, using a variety of com-
mercially available antibodies against AGEs, such as 
N- ε -(carboxymethyl)lysine (CML), N- ε -(carboxyethyl)
lysine (CEL), and ALEs, the most popular being 4-
hydroxynonenal (HNE)- and malondialdehyde (MDA)-
adducted proteins. The content of AGEs and ALEs in 
tissue and body ﬂ uids has been correlated with diﬀ erent 
oxidative-stress based diseases. For instance, the serum 
levels of CML, one of the most studied AGEs, are asso-
ciated with the severity of diabetes-related disease, 
including retinopathy [9] and microangiopathy [10], 
chronic kidney disease, as well as with the formation and 
acceleration of diabetic and non-diabetic atherosclerotic 
lesions [11]. CML was also found to be elevated in cere-
brospinal ﬂ uid of patients with amyotrophic lateral scle-
rosis [12], and the tissue level of CML in cortical neurons 
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94 G. Aldini et al. 
mechanisms, including the dysfunction of the proteins 
undergoing the oxidative modiﬁ cation, protein polymer-
ization, signal transduction, immunoresponse, and RAGE 
activation; (3) compounds eﬀ ective as inhibitors of 
AGEs/ALEs formation or able to block their biological 
eﬀ ects have been found to signiﬁ cantly ameliorate diﬀ er-
ent oxidative-based diseases. 
 Hence, AGEs/ALEs are now considered as promising 
drug targets, and a substantial eﬀ ort is dedicated to delve 
into the molecular strategies aimed at preventing, reduc-
ing, or removing these protein oxidation products [18,19]. 
The diﬀ erent molecular approaches thus far reported can 
be grouped by considering at which level of the damaging 
AGE/ALE cascade they are eﬀ ective and in particular if 
they act by inhibiting the AGE/ALE formation, accelerat-
ing their catabolism or blocking their biological eﬀ ects. 
 The ﬁ rst level of action, the inhibition of AGE/ALE 
formation, also consists of diﬀ erent approaches, which 
target the diﬀ erent inducers (ROS, metal ions) and inter-
mediate products (mainly reactive carbonyl species (RCS)) 
involved in the AGE/ALE formation. Antioxidants, metal 
ion chelators, and reactive carbonyl compound quenchers 
represent the most promising approaches so far reported 
for inhibiting AGE/ALE formation, in both  in vitro and 
 in vivo conditions. In some cases, as found for both natu-
ral and synthetic compounds, the inhibition of AGEs/
ALEs formation does not proceed through a single speciﬁ c 
mechanism but implicates multiple mechanisms, involv-
ing at least two of the following ones: antioxidant, metal 
ion chelation, and RCS quenching (reactions with RCS 
preventing their binding to vital macromolecules). Belong-
ing to this ﬁ rst group of approaches, also the xenobiotics 
that act by potentiating the endogenous detoxiﬁ cation sys-
tem devoted to the metabolization/detoxiﬁ cation of all the 
endogenous compounds involved in the AGE/ALE forma-
tion. Such a protective system consists of non-enzymatic 
and enzymatic antioxidants (compounds that prevent 
undesired oxidation by reacting with oxidants or oxidation 
intermediates), the enzymes including superoxide dis-
mutase (SOD), catalase (CAT), and glutathione peroxi-
dase (GPX), as well as of enzymes involved in the 
metabolic inactivation of reactive carbonyl derivatives, 
which include both phase I enzymes, namely aldehyde 
dehydrogenases (ALDHs), aldo-keto reductases (AKRs) 
and carbonyl reductase (CBR), and phase II enzymes, that 
is, glutathione  S -transferases (GSTs) [20]. 
 The second level of intervention involves accelerating 
the catabolism of already-formed AGEs/ALEs; this can be 
achieved by potentiating the endogenous proteolytic sys-
tem or by using xenobiotics that are able to catalytically 
degrade AGEs/ALEs. 
 The third level of intervention, which is also the most 
innovative, consists of blocking the biological response of 
AGEs/ALEs. Such an approach has emerged in parallel to 
the discovery of the receptor for AGEs and ALEs such as 
RAGE and galectin-3 [21]. It should be noted that such an 
approach permits the blocking of the damaging eﬀ ect 
induced not only by endogenously formed AGEs/ALEs 
but also by exogenously derived AGEs/ALEs. 
 In summary, AGEs/ALEs are involved as pathogenetic 
factors in some oxidative-based diseases including athero-
sclerosis, diabetes, and Alzheimer ’ s disease (AD), and are 
now recognized as promising drug targets. On these 
grounds, several molecular approaches have been described 
with the aim of inhibiting the damaging response induced 
by AGE/ALE formation. The aim of the present review is 
to systemically describe the molecular approaches thus far 
reported with a particular view of the rational drug design 
approach used. Compounds and strategies will also be 
critically commented on and their limits highlighted. 
 Inhibitors of ALE/AGE formation (GA) 
 Several molecular approaches have been considered for 
inhibiting AGE/ALE formation, and such diversity is due 
to the complex reactions leading to the AGE/ALE forma-
tion, which involves diﬀ erent inducers, precursors, and 
intermediates. In particular, as better described in the 
paper entitled  “ Advanced glycoxidation and lipoxidation 
end products (AGEs and ALEs): an overview of their 
mechanisms of formation ” and published in this series, 
two main pathways are involved in the AGE formation. 
The former is based on the reaction of reducing sugars 
(any sugar that either has an aldehyde group (aldoses) or 
is capable of forming one in solution through keto-enol 
isomerism (ketoses)) with the protein primary amino 
groups (the amino terminus and the  ε -amino group of 
Lys), followed by metal ion catalyzed rearrangements. 
The latter involves the reaction of RCS such as glyoxal 
(GO), methylglyoxal (MG), and 3-deoxyglucosone 
(3-DG; Figure 1) with the nucleophilic protein sites, and 
in particular Arg, Lys, and Cys. The RCS acting as AGE 
precursors are generated by either sugar or AGEs decom-
position/autoxidation, a series of reactions which are 
catalyzed by metal ions. ALEs are generated by only one 
pathway, based on the covalent adduction of lipid-
derived RCS (HNE, GO, and MDA) with Arg, Lys, His, 
and Cys nucleophilic residues. The RCS acting as ALE 
precursors are generated by the lipid peroxidation cas-
cade, and hence, several oxidative stress inducers and 
propagators impact their formation, including ROS and 
metal ions. 
 By considering the diverse pathways leading to AGE/
ALE formation, the following molecular strategies for the 
inhibition of their formation can be considered, based on 
the use of the following: (1) antioxidants, able to inhibit 
the lipid peroxidation cascade as well as the radical-based 
reactions involved in AGE formation; (2) metal ion chela-
tors, inhibiting diﬀ erent oxidative pathways such as those 
leading to ROS production, hydroperoxide decomposition, 
sugar and AGE decomposition to RCS; (3) compounds 
able to quench RCS which act as AGE and ALE precur-
sors. Furthermore, the ﬁ rst two mentioned approaches can 
be seen as indirect strategies since they prevent the forma-
tion of AGE and ALE precursors, while the last one is a 
direct approach in which the compounds react with the 
already-formed RCS, deactivating them and promoting 
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their rapid excretion. The above-mentioned approaches 
are grouped and described below (Figure 2). 
 Multifactorial etiology of post-translational modiﬁ ca-
tions of proteins/lipids would serve as a rationale for multi-
target-oriented interventions in anti-AGE/ALE therapeutic 
strategy. Combination therapies that simultaneously target 
multiple pathways may obviously be more successful than 
those that modify a single pathway. This approach also 
decreases the risk of side eﬀ ects and is economical. 
 Indirect inhibition mechanisms (MS) 
 Antioxidants 
 Irreversible AGEs were shown to be formed via a sequence 
of glycation and oxidation reactions [1 – 3]. Under physi-
ological conditions, glucose, like other  α -hydroxyalde-
hydes, can enolize and reduce molecular oxygen. This 
process is catalyzed by transition metals yielding reactive 
 α -ketoaldehydes and oxidizing free radical intermediates 
[22]. The ketoamine Amadori products also undergo 
autoxidation, contributing to the oxidative damage of pro-
teins exposed to hyperglycemia [1,2]. At an early stage in 
this research, the terms  “ autoxidative glycosylation ” and 
 “ glycoxidation ” were introduced for the above-mentioned 
processes [1], to emphasize the importance of oxidation 
chemistry in AGE formation. 
 As shown in the classical experiments of [22], glycox-
idation and cross-linking of collagen as a model protein 
exposed to glucose  in vitro was strongly inhibited under 
antioxidative conditions (nitrogen atmosphere and metal 
chelators). Antioxidative conditions had no eﬀ ect on gly-
cation per se measured by the degree of covalent attach-
ment of the radiolabeled glucose. 
 In addition to the above-mentioned autoxidation pro-
cesses, the oxidative stress in hyperglycemia would be 
PUFAs/sugars
Oxidative and non
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Reactive carbonyl species
(RCS)
proteins
AGEs-ALEs
lysosomal and
proteasomal system
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n
 Figure 2. Molecular intervention strategies to inhibit and degrade AGEs and ALEs. 
O
H
O
H
C
CH2
O
CHOH
CHOH
CH2OH
OH
O
H
O
H3C
Glyoxal Methylglyoxal 3-Deoxyglucosone
 Figure 1. Main reactive carbonyl species: glyoxal, methylglyoxal, and 3-deoxyglucosone. 
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enhanced by generation of ROS occurring at mitochon-
drial level as a consequence of the increased intracellular 
glucose metabolism [23,24]. 
 Hyperglycemia does not only generate more ROS but 
also attenuates endogenous antioxidative mechanisms 
through glycation of scavenging enzymes. Excessive 
consumption of NADPH by the polyol pathway in hyper-
glycemia may result in the depletion of glutathione 
(GSH). 
 Taking into consideration the oxidation component(s) 
of advanced glycation, pharmacological intervention by 
antioxidants represents a reasonable therapeutic strategy 
aimed against AGE formation. 
 Protective eﬀ ects of exogenously administered antioxi-
dants have been extensively studied in chemical and ani-
mal models of glycoxidation, mostly in relation to the 
development of diabetic complications. Antioxidants and 
chelators were found to inhibit the formation of glycoxida-
tion products, without a signiﬁ cant eﬀ ect on the extent of 
the protein glycation. Antioxidants may thus dissociate 
glycoxidative changes caused by the exposure of protein 
to glucose from the incorporation of the monosaccharide 
into the protein itself. 
 There are countless experiments and studies of anti-
oxidant action on processes of non-enzymatic glycation 
covered by excellent reviews (see, e.g., [25]). Most of 
these studies are aimed at modeling the situation in a 
hyperglycemic milieu relevant to diabetes. The eﬀ ect of a 
typical chain-breaking antioxidant on glycoxidation can 
be exempliﬁ ed by the extensive studies performed on the 
pyridoindole antioxidant drug stobadine (Figure 3). Under 
conditions of an experimental glycation model  in vitro, 
comprising bovine serum albumin incubated in the pres-
ence of glucose, stobadine inhibited glycation-related 
absorbance and ﬂ uorescence changes of the protein as 
well as the yield of 2,4-dinitrophenyl-hydrazine-reactive 
carbonyls with an eﬃ  cacy comparable with that of the 
reference antioxidant trolox, and more eﬃ  ciently than did 
the glycation inhibitor aminoguanidine. Since stobadine 
did not aﬀ ect the early steps of glycation measured as 
Amadori product formation and the covalent binding of 
glucose, the observed protective eﬀ ects were explained by 
the ability of the drug to eliminate free radical intermedi-
ates of glycoxidation reactions, operative after the preced-
ing glycation steps [26,27]. 
 Using a model of streptozotocin (STZ)-diabetic rats 
 in vivo , stobadine was found to attenuate pathological 
changes in the diabetic myocardium [28,29] and kidneys 
[30 – 32], to decrease matrix collagen cross-linking [30] 
and to reduce plasma cholesterol and triglyceride levels in 
diabetic animals [28,33]. Stobadine treatment normalized 
calcium homeostasis in diabetic heart and liver [33] and 
produced beneﬁ cial eﬀ ects on liver and leukocyte function 
in diabetic rats [34,35]. 
 Long-term treatment of diabetic animals with stobadine 
led to a marked delay in the development of advanced 
stages of cataract [36] and inhibited the development of 
retinal morphological abnormalities and lipid peroxida-
tion, even under poor glycemic control [37]. 
 Treatment of diabetic animals with stobadine partially 
prevented the decrease in conduction velocity of the sci-
atic nerve measured  in vitro. The protective eﬀ ect was 
enhanced by co-therapy with vitamin E. On the other 
hand, resistance to ischemic conduction failure, elevated 
in diabetic animals, was not found to be aﬀ ected by any 
of the drugs studied [38,39]. 
 The antioxidants butylated hydroxytoluene (BHT, 
Figure 2) and trolox (6-hydroxy-2,5,7,8-tetramethyl 
chroman-2-carboxylic acid, Figure 2) were reported to pro-
tect sugar-induced cataractogenesis in cultured rat lens [40], 
and BHT was found to prevent or delay also galactosemic 
cataractogenesis in rats [41]. BHT ameliorated nerve 
dysfunction in STZ diabetic and galactosemic rats [42]. 
 Several observational studies on age-related and dia-
betic cataract have suggested that antioxidant micronutri-
ents, such as  α -tocopherol, retinol, and ascorbic acid, may 
help to protect against cataractogenesis [43 – 45]. However, 
other studies reported non-signiﬁ cant eﬀ ects or even 
negative results [46,47]; for review, see [48]. 
 Antioxidant action of natural ﬂ avonoids may be eﬀ ec-
tive in reducing the oxidative pathways conducive to 
advanced glycation. It is beyond the scope of this review 
to give a thorough survey of the abundant literature cover-
ing numerous studies on the antioxidant activity of ﬂ a-
vonoids. The key structural features required for the high 
antioxidant eﬃ  cacy of ﬂ avonoids are summarized in Bors ’ 
criteria [49,50]. The current data on natural polyphenols 
relevant to glycation-related pathologies demonstrate that 
ﬂ avonoids may play a role in the prevention of cataract 
[51,52] and some complications of diabetes [53 – 55]. Anti-
oxidant therapy may be of great interest in diabetic patients. 
Despite encouraging results obtained by  in vitro and 
 in vivo studies, a number of clinical intervention trials 
aimed at elucidating the eﬀ ects of antioxidant micronutri-
ents (vitamins E and C,  β -carotene, and retinol) on the 
development of age-related and diabetic cataract, and 
other diabetic complications failed to show any beneﬁ cial 
eﬀ ects. However, it is still too early to reach a deﬁ nitive 
conclusion on the clinical beneﬁ ts of antioxidants. 
 Metal chelators 
 ROS and free transition metal ions have been recognized 
as key players in advanced glycation. Redox metal chela-
tors may therefore eﬃ  ciently interfere with the process at 
the stage of both  “ autoxidative glycosylation ” and  “ gly-
coxidation ” [1]. Chelation, which is suﬃ  cient to inhibit 
AGE formation independently of carbonyl trapping, is a 
common characteristic of many drugs with multiple func-
tional groups [56,57]. The chelating activity of inhibitors 
of AGE formation varies widely, yet under  in vivo condi-
tions a complete chelation of all free redox metal ions may 
not be desirable. 
 The iron chelator diethylenetriaminepentaacetic acid 
(DETAPAC, Figure 3) eﬃ  ciently inhibited autoxidation of 
glucose and glycoxidation changes of model proteins 
exposed to high glucose in experimental glycation models 
 in vitro [58 – 63]. The potent iron chelator, desferrioxamine, 
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strong metal-chelating action was reported for numerous 
inhibitors of AGE formation and AGE breakers, including 
pyridoxamine (PM) [79], tenilsetam [80 – 82], carnosine 
[83,84], metformin [85 – 88], OPB-9195 [84], angiotensin 
converting enzyme inhibitors, and angiotensin II receptor 
blockers [89]. For most inhibitors of AGE formation, it is 
diﬃ  cult to ascertain the contribution of alternative mech-
anisms of action, as trapping of carbonyl species, chela-
tion of metal ions or scavenging of reactive oxygen 
intermediates. 
 To distinguish between the carbonyl trapping and chela-
tion by AGE inhibitors, Price et  al. measured the chelating 
activity of the inhibitors by determining the IC 50 values 
for the rate of copper-catalyzed autoxidation of ascorbic 
acid in phosphate buﬀ er. The apparent binding constants 
of copper ranged from approximately 2 mM for amin-
oguanidine and PM, to 10 – 100  μ M for carnosine, 
phenazinediamine, OPB-9195, and tenilsetam. The AGE 
breakers, phenacylthiazolium and phenacyldimethylthi-
azolium bromide, and their hydrolysis products, were 
found to be the most potent inhibitors of ascorbate oxida-
tion [56]. Based on the above-mentioned results, it was 
concluded that, at millimolar concentrations of AGE 
inhibitors used in many  in vitro studies, inhibition of AGE 
formation results primarily from the chelating or antioxi-
dant activity of the AGE inhibitors, rather than from their 
carbonyl quenching activity. At therapeutic concentra-
tions, the chelating activity of inhibitors of AGE formation 
and AGE-breakers may contribute to their inhibition of 
AGE formation. 
N
N
N
COOH
HOOC
HOOC
COOH
HOOC
LR-59
ON
Cl
NH
Cl Cl
O
COOH
Stobadine
N
N
H
H
O
HO
COOH
Trolox Butylated hydroxy toluene
(BHT)
OH
NH2NH
NH
H2N
TETA
HOOC
COOH
HO COOH
Citric acidDETAPAC 
2
LR-90
HOOC
NHNH
O O CH2
Cl
 Figure 3. Relevant xenobiotics acting as antioxidants (ﬁ rst row) and metal chelators (second and third rows). 
inhibited the formation of CML in experimental glycation 
models  in vitro [64] and accumulation of AGEs under dia-
betic conditions [65,66]. Desferrioxamine therapy amelio-
rated nerve dysfunction in STZ diabetic rats [67]. 
 Triethylenetetramine (TETA, Figure 3) has recently 
been identiﬁ ed as a highly selective divalent chelator of 
copper, and to a lesser extent of iron, preventing or revers-
ing diabetic copper overload. Alterations in copper and 
iron homeostasis were reported in diabetic subjects [68,69]. 
In diabetes, AGE-modiﬁ ed proteins can act as endogenous 
chelators, thus increasing the copper content of organs such 
as the heart and kidneys. TETA tightly binds and extracts 
excess systemic Cu(II) into the urine whilst neutralizing its 
catalytic activity [70 – 75]. Chelation of transition metals by 
TETA signiﬁ cantly attenuated structural and functional 
changes in the heart of the Zucker type 2 diabetic rat [73] 
and ameliorated nerve dysfunction in STZ diabetic rats 
[42,67,76]. In diabetic rat lenses, TETA decreased the lev-
els of MG and 3-DG, the most potent precursors of AGEs, 
as well as of AGEs themselves [77]. 
 Dietary supplementation of citric acid (2-hydroxypro-
pane-1,2,3-tricarboxylic acid, Figure 3), a relatively non-
speciﬁ c chelator, signiﬁ cantly prevented structural and 
functional changes in the heart of Zucker diabetic rats [73] 
and inhibited development of cataract, proteinuria and 
ketosis in STZ diabetic rats [78]. 
 In their recent review, Nagai et  al. proposed that the 
chelation activity may be responsible for AGE formation 
inhibitory activities of a variety of drugs commonly used 
for the treatment of diabetic complications [57]. Indeed, 
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 Interestingly, compounds of the so-called LR series 
(phenyl ureido derivatives as seen in the LR-90 and 
LR-59 examples, Figure 3), the mechanism of which is 
almost exclusively ascribable to a very potent metal 
chelation, were found to prevent dyslipidemia, diabetic 
nephropathy, and retinopathy in several animal models 
with a protective eﬀ ect comparable, if not better, with 
that exerted by PM or aminoguanidine [90 – 92]. Notably, 
LR-90 also shown marked anti-inﬂ ammatory properties 
(as demonstrated in human monocytes) and might 
therefore have additional protective eﬀ ects against dia-
betic vascular complications [93]. Collectively, these 
results emphasize the prominent role that metal ions 
elicit in AGE/ALE formation thus indicating that their 
chelation can represent a very eﬀ ective therapeutic 
strategy provided that the induced eﬀ ect does not alter 
the ﬁ ne homeostasis of the sequestered metal ions in 
human body. 
 Direct scavenging (trapping) of reactive carbonyls (GA) 
 Several reviews have explicitly discussed the biological 
activities as well as the potential therapeutic applications 
of RCS quenchers (see, e.g., [94,95]), and for this reason, 
these aspects will be not extensively covered but the lit-
erature referred to. In the present chapter, the RCS 
quenchers will be classiﬁ ed on the basis of the functional 
groups involved in the quenching reactions and the 
structure – activity relationship discussed, together with a 
detailed explanation of their mechanism in terms of reac-
tivity and selectivity. 
 The analysis of carbonyl quenchers should start from 
the key concept that their biological activity is not based 
on ﬁ ne recognition process between a ligand and a given 
biomacromolecular target but on a speciﬁ c covalent 
reaction between a quencher and a given reactive carbo-
nyl derivative. This implies a truly revolutionary change 
in the design approaches since all moieties of a ligand 
participate in the binding event, despite with a diﬀ erent 
relevance, while the quenching activity is heavily inﬂ u-
enced by the presence of few reactive groups and the 
remaining part of the molecule acts rather as an inert 
framework which bears the key centers and at most 
modulates their reactivity and/or inﬂ uences the overall 
pharmacokinetic proﬁ le. Therefore, the quencher design 
should shift attention from interacting groups which are 
chosen to stabilize short-range interactions with the cru-
cial residues in the receptor binding site (e.g., H-bonds 
or hydrophobic contacts, [96]) toward reactive centers 
which should be selected to match the speciﬁ c electro-
philicity of the RCS, thus promoting the formation of 
covalent adducts [97]. 
 In order to better understand the rational drug design 
of the compounds removing RCS so far reported, a brief 
description of the chemical reactivity of RCS acting as 
AGE and ALE precursors is reported here below. RCS 
can be ﬁ rstly grouped into three main chemical classes: 
dialdehydes ( α -dialdehydes such as GO and  β dialdehydes 
such as MDA), keto-aldehydes (i.e.,  α oxoaldehydes such 
as 3-DG, MG) and  α , β -unsaturated carbonyls. Generally 
speaking, the chemical reactivity of RCS is not ascribable 
to the sole carbonyl moiety but is essentially due to the 
combination of more chemical functions, which act syn-
ergistically making the compounds extremely reactive and 
hence damaging. 
 From a very general point of view, RCS can be seen as 
electrophilic compounds which require nucleophilic 
quenchers to yield condensation reactions which can be at 
least qualitatively predicted by the electronic properties of 
the reactants as computed by quantum mechanical param-
eters [98]. It should be underlined that electrophiles do not 
react indiscriminately with nucleophiles, but, as discussed 
by LoPachin and coworkers [99], the reactants can react 
provided that they have similar degree of polarizability, as 
predicted by Pearson ’ s Hard and Soft, Acids and Bases 
(HSAB) theory [100]. 
 As described above, both AGE and ALE precursors 
contain at least two electrophilic moieties which can 
clearly explain their unique reactivity. Thus, the enhanced 
chemical reactivity of  α -dicarbonyls is mainly associated 
with the powerful activation of one electron-withdrawing 
carbonyl group on the other [101]. The enhanced reactiv-
ity of such compounds make them able to react at the 
same time with more nucleophilic centers such as two 
Lys residues to form protein cross-linking adducts such 
as imidazolium cross-links (i.e., the GO – Lys dimer, 
GOLD) and imidazole cross-links (i.e., the GO – Lys – Arg 
dimer, GODIC). Again, the speciﬁ c reactivity of 
 α , β -unsaturated carbonyls is mainly ascribable to their 
capacity to yield Michael-type adducts due to the marked 
reactivity of  β carbon atom that is added to that of the 
carbonyl group, which however conserves the possibility 
to condense with suitable nucleophilic groups [102]. In 
some cases, their reactivity is further modulated by the 
vicinal groups, such as the hydroxyl group in HNE or the 
keto function in 4-oxo-2-nonenal (ONE), that enhance 
the electrophilic property of  α -carbon atom by electron-
withdrawing eﬀ ects. 
 On these grounds, it comes as no surprise that all 
reported quenchers are endowed with one or more nucleo-
philic centers, which diﬀ er in their physicochemical 
properties as well as in the capacity to trap diﬀ erent car-
bonyl species. As a trend, compounds possessing only 
one strong nucleophilic group act by a one-step mecha-
nism, and as such they are rarely endowed by a suitable 
selectivity, trapping also physiological carbonyls. Diﬀ er-
ently, scavengers with two or more reactive groups gener-
ally show a softer reactivity, act by multistep mechanisms, 
and possess a satisfactory selectivity, thus avoiding the 
depletion of physiological compounds. By considering 
the number of their reactive centers, the reported carbo-
nyl quenchers can be subdivided into monoreactive and 
polyreactive molecules. Based on the chemical nature of 
their reactive groups, the former can be further classiﬁ ed 
into thiol-containing compounds, guanidine and hydra-
zine derivatives, and  β dicarbonyl analogs, while the 
latter can be grouped into heterocycle-based compounds, 
amino derivatives, and phenols and polyphenols. 
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 Monoreactive molecules 
 Thiol-containing compounds. The prototypal example of 
thiol-containing carbonyl scavenger is oﬀ ered by GSH, 
the endogenously reducing tripeptide ( γ -L-glutamyl-L-
cysteinylglycine) involved in several antioxidant processes 
given its capacity to prevent cellular damage caused by 
ROS such as free radicals and peroxides [103]. Besides 
the known antioxidant properties, mainly based on its abi-
lity to oxidize into reversible disulﬁ de species [104], GSH, 
due to the marked sulfur nucleophilicity, can also yield 
covalent adducts with endogenous or xenobiotic electro-
philic compounds [105]. Once adducted, the peptide loses 
its terminal residues (L-glu and gly), thus yielding the 
corresponding mercapturic acid which detoxiﬁ es the 
quenched electrophile rendering it more hydrophilic and 
easier to be excreted [106]. 
 Although several electrophilic species can spontane-
ously react with GSH (as ﬁ rstly demonstrated for  α ,
 β -unsaturated aldehydes by Esterbauer [107]), the addition 
can also be catalyzed by cytosolic GSTs [108], which rep-
resent a family of versatile enzymes able to catalyze the 
nucleophilic conjugation of GSH with a wide spectrum of 
electrophiles. Concerning the detoxiﬁ cation of ALE pre-
cursors [109,110], several studies revealed the involve-
ment of GST enzymes as suggested by their upregulation 
in initial stages of oxidative stress. Among the involved 
GST isozymes, GSTA4-4 [111] emerges for its high cata-
lytic eﬃ  ciency toward alkenal substrates, such as HNE, 
even though other subtypes can surely contribute to the 
RCS detoxiﬁ cation. Notably, this enzymatic HNE addition 
shows a certain degree of stereoselectivity, with a relative 
preference for ( R )- versus ( S )-HNE which is presumably 
due to the participation of the hydroxyl moiety to the sub-
strate recognition [112]. Such a selectivity tends to gener-
ate preferentially deﬁ ned sets of diastereoisomeric adducts 
with potential biological implications for toxicity and 
excretion [113]. 
 Concerning the dicarbonyl detoxiﬁ cation, it should be 
reminded that the GSH serves as a cofactor for glyoxalase 
enzymes [114], which catalyze the conversion of dicarbo-
nyls into non-toxic products as a part of the cellular defense 
system against glycation [115]. Given the remarkable 
nucleophilicity of the thiol function and, consequently, its 
facile reactivity with unsaturated carbonyls [116], cysteine 
derivatives are more able to quench  α , β -unsaturated alde-
hydes, through a Michael addition, compared to dicarbo-
nyls even though also these latter can be trapped by 
formation of the corresponding thioacetals. Moreover, 
Nomi and coworkers have recently demonstrated that 
dicarbonyls can react with N-terminal group of the gluta-
mate residue yielding stable dioxomorpholine adducts 
which appear to be favored by the  α position of the pri-
mary amine (compared to the N-terminus of other pep-
tides). This cyclic adduct should represent the most 
important products coming from quenching reactions 
between dicarbonyls and GSH [117]. 
 Free cysteine and N-acetyl cysteine (NAC) [118] can 
be seen as both precursors of GSH [119] and compounds 
able to directly quench RCS with a concentration-
dependent activity comparable with that of the non-
enzymatic GSH addition [120]. Similar quenching 
activities are also shown by cysteamine (2-aminoethane-
thiol) and cysteine methyl ester, thus conﬁ rming that 
the carboxyl terminus is not involved in quenching 
mechanism [121,122]. Interestingly, also  taurine (2-
aminoethanesulfonic acid), that can be seen as an oxi-
dized form of cysteamine, was reported to be able to 
directly quench MDA giving ﬂ uorescent 1,4-dihydropyri-
dine and non-ﬂ uorescent enaminal derivatives, thus sug-
gesting that the modulation of carbonyl stress may be 
included among the biological functions of taurine [123]. 
 Penicillamine (3-mercaptovaline) and its analogs [124] 
show a signiﬁ cantly greater activity toward dicarbonyls 
which can be explained by considering their ability to 
yield stable thiazolidine adducts, which results from 
nucleophilic ring closure of the initial imine intermediate 
[125]. Such a mechanism suggests that, although pen-
icillamine is described here for structural analogy with the 
other sulfur-containing quenchers, it can be seen as an 
example for polyreactive quencher whose mechanism 
requires the concerted involvement of both reactive cen-
ters. The participation of both moieties can also explain 
the observed stereoselectivity since D-penicillamine is 
slightly more active than the L-enantiomer probably 
because it exposes the reactive groups in an arrangement 
more favorable to the ﬁ nal cyclization. Similarly, the 3,3 
dialkyl substitution may favor the ring closure preventing 
the reverse hydrolysis reaction [122]. The relevance of 
alkyl substitution is further conﬁ rmed by the notable 
activity of omo-derivative of penicillamine, namely 
3-methyl, 3-ethyl cysteine (MEC) whose quenching abil-
ity induces apoptosis on malignant melanoma cell lines as 
reported by Wondrak and coworkers [126]. 
 Lastly, lipoic acid (6,8-dithiooctanoic acid), a naturally 
occurring nutraceutical [127], is a well-known antioxi-
dant able to directly quench free radicals as well as to 
regenerate other antioxidants due to its redox equilibrium 
between the reduced thiols and the oxidized disulﬁ de. It 
is also able to trap both ALE and AGE precursors due to 
the presence of two nucleophilic thiols [128,129], thus 
resulting in protective eﬀ ects against oxidative-based 
diseases as clearly demonstrated by animal models for 
diabetes, non-alcoholic steatohepatitis, and ischemia 
[130]. As recently evidenced, the protective eﬀ ect of lipoic 
acid can also be due to its restorative action on aldehyde 
dehydrogenase, ALDH2, whose activity is upregulated by 
about 60% after pretreatment with lipoic acid so inducing 
a signiﬁ cant decrease in all carbonyl species [131]. 
 However, it should be emphasized that, despite the 
strong sulfur nucleophilicity, thiol-containing drugs are 
potentially toxic compounds since they can react with 
cysteine thiol functions yielding protein-drug mixed dis-
ulﬁ des. These adducts can impair the physiological func-
tions of the modiﬁ ed proteins, even though cells and 
plasma possess protective dethiolation processes which 
are able to regenerate critical protein thiols [132]. More 
importantly, thiol-containing drugs can behave as haptens 
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when the mixed disulﬁ des become antigenic determinants 
and initiate an immune response which can culminate in 
hypersensitivity and, consequently, idiosyncratic reactions 
(IDRs) depending on the body ’ s capacity to detoxify these 
adducts [133]. 
 Guanidine and hydrazine derivatives. Due to the presence 
of more electron-rich nitrogen atoms, aminoguanidine 
(2-Aminoguanidine, aka Pimagedine [134]; Figure 3) pos-
sesses the necessary nucleophilicity to rapidly react with 
both ALE and AGE precursors albeit through diﬀ erent 
reaction mechanisms [135]. The  α , β -unsaturated alde-
hydes can condense with aminoguanidine through Michael 
addition or imino formation [136], while dicarbonyls cycl-
ize with the formation of 1,2,4 triazine analogs [137]. 
Aminoguanidine was found to reduce tissue levels of 
AGEs in experimental models of diabetes as well as to 
retard the development of several AGE-related patholo-
gies, including diabetic vascular diseases, neuropathy, 
retinopathy, nephropathy, and cataract [67,135,138 – 152]. 
However, due to its high reactivity, aminoguanidine does 
not possess a suitable selectivity trapping also physiologi-
cal carbonyls [136], and indeed, phase III clinical trials for 
aminoguanidine were discontinued because it induced 
vitamin B 6 deﬁ ciency [153]. Not to mention that amin-
oguanidine has other pharmacological activities since it 
inhibits both nitric oxide synthase [154] and semicarbazide-
sensitive amine oxidase (SSAO) [155]). Despite the men-
tioned drawbacks, several aminoguanidine derivatives were 
proposed as carbonyl quenchers mainly with a view to 
removing the promiscuous biological activities as well as 
to improving the pharmacokinetic proﬁ le by enhancing 
the lipophilicity. Among them,  β -resorcylidene amino-
guanidine (RAG) [156]; Figure 3) and ALT-946 [N-(2-
acetamidoethyl) hydrazine-carboximidamide hydrochloride] 
(Figure 3) have attracted considerable interest for the 
eﬃ  cient anti-glycation and anti-oxidant eﬀ ects in both 
animal studies and  in vitro experiments with minimal 
inhibitory eﬀ ects on nitric oxide synthase [157 – 159]. In 
addition to the indirect eﬀ ect of all anti-diabetic agents on 
AGE formation by lowering blood glucose level, some 
anti-diabetic agents are also direct inhibitor of AGE forma-
tion and can be seen as aminoguanidine derivatives. Thus, 
the anti-diabetic agent metformin (1,1-dimethylbiguanide; 
Figure 4) was reported to decrease AGE formation  in vitro , 
most likely by eliminating reactive carbonyl precursors [88,
160 – 162]. In clinical studies, metformin reduced the levels 
of reactive dicarbonyls and AGEs [86,163]. These mecha-
nisms contribute to medicinal eﬀ ects of metformin beyond 
the beneﬁ ts expected from its anti-hyperglycemic eﬀ ect. 
 When serum albumin was incubated  in vitro with glu-
cose, ribose, or ascorbate, OPB-9195 (2-isopropylidene-
hydrazono-4-oxo-thiazolidin-5-yl acetanilide; Figure 4),
 a quite complex derivative in which the aminoguanidine 
moiety is embedded in a thiazolidin-5-acetanilide sys-
tem, prevented AGE formation more eﬃ  ciently than 
aminoguanidine, aﬀ ecting especially the generation of 
pentosidine and carboxymethyl lysine [164]. In animal 
studies using diabetic rats, OPB-9195 normalized AGE 
levels and aﬀ orded neuroprotective, renoprotective, and 
angioprotective eﬀ ects [157,165 – 170]. Lastly, ALT-462 
(4-amino-3-hydrazino-5-isopropyl-4H-1,2,4-triazole 
dihydrochloride; Figure 4) can be seen as a cyclic ana-
logue of the aminoguanidine in which the reactive moi-
ety is masked in a triazole ring and shows a 
dose-dependent scavenging activity at least 20 times 
more potent than aminoguanidine [171]. 
 Besides guanidine, a second nitrogen atom containing 
electron-rich function is represented by hydrazine (or hydraz-
ide) group [172]. Hydralazine (1-hydrazinylphthalazine, 
H2N NH
NH2
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 Figure 4. Relevant monoreactive carbonyl quenchers. 
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Figure 3) and dihydrohydralazine are the lead compounds 
of a series of hydrazine derivatives endowed by a marked 
scavenging ability toward both ALE and AGE precursors. 
Like aminoguanidine, hydrazine derivatives can react with 
 α , β -unsaturated aldehydes through Michael addition or 
imine formation [136,173], while dicarbonyls cyclize 
yielding diazine analogs [174]. Yet again, due to high 
hydrazine nucleophilicity, hydralazine lacks suitable 
selectivity trapping also physiological carbonyls through 
the formation of stable imine derivatives [136]. Moreover, 
hydralazine and dihydrohydralazine also show a promis-
cuous activity since they are well-known vasodilator 
agents which have been used for the treatment of essential 
hypertension since the 1950s [175]. Despite the mentioned 
pitfalls, such compounds have attracted considerable inter-
est for their excellent scavenging activity toward reactive 
carbonyls, and indeed, they have been proven to be thera-
peutically eﬃ  cient in preventing AGE and ALE formation 
in several oxidative-stress based disorders including dia-
betes, atherosclerosis, and Alzheimer disease [122,
173,174]. Hence, it is not surprising that numerous hydra-
zine-containing derivatives have been proposed with a 
view to separating the scavenging activity from the vaso-
active eﬀ ect, quite a feasible task considering that scav-
enging requires only the hydrazine group and, unlike 
vasoactivity, is rather independent on the remaining part 
of the molecule and (b) increasing hydrophobicity to 
enhance the pharmacokinetic proﬁ le and especially to 
increase blood – brain barrier permeability. Among the 
hydrazine derivatives, bisvanillyl-hydralazone shows 
notable antioxidant, carbonyl scavenger, and anti-apop-
totic properties, thus resulting in a particularly eﬃ  cient 
agent for therapeutic applications in atherosclerosis [176]. 
Studies involving already-marketed drugs with a hydra-
zine (or hydrazide) function (e.g., isoniazid, iproniazid, 
and phenelzine) showed that all these drugs induce a sig-
niﬁ cant carbonyl stress inhibition correlated with a reduc-
tion of athero sclerotic lesion development [177]. By 
considering that oxidative damage is a major pathological 
feature of the Alzheimer disease, some authors developed 
new hydrazine derivatives endowed by extended aromatic 
systems able to interact with the amyloidogenic core of 
A β through p-p-stacking interactions so as to intercalate 
between A β ﬁ brils. In this way, the quenchers so obtained 
(e.g., 2-hydrazino-4-phenylthiazole, indole-3-acetic hyd-
razide, and carbazochrome) induced a promising reduc-
tion of both A β misfolding and A β protein modiﬁ cation 
by RCS, thus suggesting their potential for further drug 
development [178]. 
 b dicarbonyl analogs. The nucleophilic reactivity of the 
 β dicarbonyl analogs toward reactive carbonyls is essen-
tially ascribable to the acidity of the  α methylene due to 
the electron-drawing eﬀ ect of the vicinal carbonyl groups. 
Although also  β dicarbonyls (as in the well-known case 
of MDA) can derive from lipid peroxidation and promptly 
react with physiological nucleophiles due to the 
extreme reactivity of their  β -hydroxyacrolein form [179], 
 β -dicarbonyl derivatives, in which the carbonyl reactivity 
is suitably modulated, may enhance their nucleophilicity 
thus resulting in very reactive carbonyl quenchers. A 
well-known example of this class of carbonyl quenchers 
is represented by edaravone (5-methyl-2-phenyl-2,
4-dihydro-3H-pyrazol-3-one; Figure 4) whose pyrazolone 
ring can be indeed seen as a cyclic (and masked) form of 
 β dicarbonyl [180]. Edaravone combines a potent free 
radical scavenging [181] with a signiﬁ cant carbonyl 
quenching activity which is mostly due to the acidic char-
acter of the methylene in position 4 [182]. Edaravone was 
approved in 2001 in Japan for the treatment of cerebral 
infarction, even though additional clinical studies are still 
necessary to verify the complete eﬃ  cacy of edaravone 
and in particular to investigate which kind of ischemic 
patients is well suited for the edaravone treatment and to 
deﬁ ne the optimal dose and therapy duration in order to 
gain a signiﬁ cant eﬃ  cacy within a reasonable therapeutic 
window [183]. 
 A recent study [184] conﬁ rmed the excellent reactivity 
of edaravone toward GO, acrolein, and HNE while evi-
dencing that it can react with  α , β -unsaturated aldehydes 
acting as a polymerizing agent and forming adducts 
characterized by a very high molecular weight since all 
monitored adducts conserve a reactivity comparable with 
that of edaravone. The capacity to yield polymeric adducts 
can explain some side eﬀ ects observed during prolonged 
edaravone treatments. Notwithstanding this, the notable 
quenching activity of edaravone prompted the development 
of derivatives mainly substituted in 4 with the aim to mod-
ulate the acidity of this carbon atom. Among them, 
TM2002 (Figure 4), which derives from the 4-substitution 
of edaravone with a furo-pyridinol moiety, appears to be 
a non-toxic inhibitor of advanced glycation and oxidative 
stress devoid of eﬀ ect on blood pressure with a neuro-
protective eﬃ  cacy comparable with that of the parent 
compound [185]. 
 By considering the known protective action of cur-
cumin and other natural  β -diketo derivatives [186,187], 
LoPachin and coworkers recently proposed a set of simpli-
ﬁ ed diketo analogs (e.g., 2-acetylcyclopentanone), which 
showed a signiﬁ cant scavenging activity toward  α , 
β -unsaturated aldehydes as well as metal ion chelation 
properties. The promising results obtained in cellular 
models of oxidative stress render these compounds 
potential candidates for the treatment of acute or chronic 
oxidative-stress based neurodegenerative conditions [188]. 
 Polyreactive compounds 
 Heterocycle-based compounds. The parent compound of 
all heterocycle-based scavengers is surely carnosine 
( β -Ala-His; Figure 5) [189,190], an endogenous peptide 
speciﬁ cally found in millimolar concentration in some 
tissues as the brain, the heart, and the skeletal muscles 
and whose multistep mechanism, mainly based on the 
ability of the imidazole ring to yield Michael addition on 
the unsaturated imine intermediate, renders it markedly 
selective toward RCS [191,192]. The remarkable proﬁ le of 
this dipeptide has prompted the development of numerous 
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derivatives which were extensively examined in recent 
reviews (see, e.g., [193,194]). While avoiding extensive 
analyses of its derivatives, it is interesting to remind here 
the two major objectives for which the carnosine ana-
logues were designed. The ﬁ rst objective was to improve 
the quenching activity while maintaining the mentioned 
selectivity, and this aim was pursued essentially by 
replacing the primary amine with more reactive moieties 
such as hydrazines, hydrazides, and diammino groups 
(e.g., [195]). The second objective involved the improve-
ment of carnosine ’ s pharmacokinetic proﬁ le since it is 
actively absorbed by intestinal transporter hPepT1 [196] 
but rapidly hydrolyzed by serum carnosinase, a speciﬁ c 
dipeptidase found in plasma and in the brain [197]. To 
this end, carnosine derivatives were created by modiﬁ ca-
tion at the peptide bond or at the histidine conﬁ guration 
(i.e., D-carnosine,  β -Ala-D-His) [198]. These simple 
examples emphasized what was already discussed in the 
introductive part, namely that the structure of the scav-
engers can be clearly subdivided into few reactive moi-
eties whose modiﬁ cation heavily inﬂ uences the quenching 
activity and the remainder, which is virtually inert and 
can be vastly modiﬁ ed to improve the pharmacokinetic 
proﬁ le. Although no longer recognized by intestinal tras-
porter, D-carnosine and its lipophilic prodrugs showed a 
quenching activity almost superimposable on that of 
L-carnosine being totally stable in human plasma [199]. 
Due to its promising bioactivity, D-carnosine underwent 
 in vivo studies revealing that it is highly eﬀ ective in 
attenuating experimental atherosclerosis and renal dis-
ease by reducing carbonyl stress and inﬂ ammation and 
that it may represent a promising therapeutic strategy in 
humans [200]. 
 The remarkable proﬁ le of both carnosine and other 
natural histidine containing peptides, as in the case of 
GHK (Gly-His-Lys), prompted also the development 
of novel short peptides more active and more stable 
than carnosine or GHK. In a recent patent, Lipotec 
(Barcelona, Spain) reported a set of tetrapeptides with a 
capacity to quench HNE and nonenal signiﬁ cantly greater 
than that of carnosine. All the reported tetrapeptides show 
the key histidine as a C-terminal residue and alanine in 
second position. Interestingly, the most active peptides 
have a 2,3-diaminopropionic acid residue as N-terminus, 
which might promote the formation of the initial imine 
intermediate [201]. 
 A second heterocycle-based natural compound is rep-
resented by thiamine (vitamin B 1 ; Figure 5) whose antig-
lycation activity can have a dual mechanism. Thiamin is 
converted in the cell to thiamin pyrophosphate (TPP), the 
coenzyme for transketolase (TK), a rate-limiting step of 
the pentose phosphate pathway [202]. TK activation could 
decrease the accumulation of glyceraldehyde-3-phosphate 
and fructose-6-phosphate during glycolysis, thus prevent-
ing AGE formation [203]. Moreover, thiamine can directly 
quench reactive carbonyls [204] due to the unique reacti-
vity of its thiazolium nucleus [205] with a mechanism 
similar to that exerted by thiamine in the enzymatic catal-
ysis [206]. A similar activity is oﬀ ered by benfotiamine 
(Figure 5), a soluble analogue of vitamin B 1 [207], which 
additionally prevents the lipopolysaccharide-induced acti-
vation of cPLA2 thus exerting a protective eﬀ ect by mod-
ulating the arachidonic acid pathways [208]. Both 
benfothiamine and thiamine were reported to be beneﬁ cial 
in experimental models of diabetic nephropathy [209,210]. 
Benfothiamine improved nerve conduction velocity in 
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 Figure 5. Relevant polyreactive carbonyl quenchers. 
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diabetic patients [211,212] and prevented vascular 
endothelial dysfunction after a high-AGE meal [213]. 
Nevertheless, recent clinical studies on patients suﬀ ering 
from diabetes (types 1 and 2), diabetic nephropathy, and 
peripheral nerve inﬂ ammation showed that benfotiamine 
does not result in signiﬁ cant reductions in plasma or uri-
nary AGEs or plasma markers of endothelial dysfunction 
and nerve inﬂ ammation compared to placebo [214,215]. 
 Tenilsetam (3-thiophen-2-ylpiperazin-2-one; Figure 4), 
a derivative initially developed as cognition-enhancing 
drug for the treatment of patients suﬀ ering from Alzheimer ’ s 
disease, shows beneﬁ cial eﬀ ects which seem to be ascrib-
able to its ability to reduce protein carbonylation by both 
directly quenching RCS and covalently attacking the 
already-glycated proteins, thus blocking the reactive sites 
for further polymerization reactions with favorable eﬀ ects 
on the AGE-derived cross-linking of amyloid plaques 
[82,216]. Despite the fact that precise quenching mecha-
nism is still unclear, the protective eﬀ ect of tenilsetam 
indicates that carbonyl quenchers may represent a 
promising therapeutic strategy to reduce intracellular 
AGE-accumulation as well to decrease the RCS-induced 
impairment in aging and neurodegeneration [217]. 
 Amino derivatives. As a preamble, it should be empha-
sized that the main reactivity that a primary amine can 
exert toward RCS involves the formation of stable imine 
derivatives. Given the good correlation between basicity 
and nucleophilicity for amine derivatives [218], a nucleo-
philicity increase is inevitably paralleled by an increase 
in the fraction of protonated forms which in fact cannot 
yield the imine formation since the protonated species 
cannot attack the carbonyl carbon atom to yield the cor-
responding carbinolamine [219]. This means that the 
imine formation may be enhanced by lowering the basi-
city of the amino group so as to increase the fraction of 
neutral species even though such an approach should be 
cautiously pursued since the imine stability increases 
when nucleophilicity decreases due to the stabilizing 
eﬀ ect of electron-drawing substituents on the C    N 
double bond [220]. This implies that amino-based scav-
engers endowed with relatively basic amines lose their 
selectivity by trapping even physiological carbonyls. Dif-
ferently stated, the reactivity of the amino groups should 
be carefully balanced to maximize the quenching activity 
without undermining the selectivity. 
 The amino reactivity is conveniently exploited by 
scavengers already examined in the previous sections. 
For example, the mechanism of carnosine reaction with 
RCS involves as a ﬁ rst step of the condensation between 
the carbonyl function and the carnosine primary amine, 
resulting in the formation of a reversible  α , β -unsaturated 
imine intermediate which serves as an intramolecular 
catalyst to favor the key Michael addition involving the 
imidazole ring [221]. Similarly, the cyclization process 
involving penicillamine with dicarbonyls starts with the 
formation of the initial imine intermediate. Nonetheless, 
the mentioned compounds were included in other sec-
tions since their quenching is heavily inﬂ uenced by the 
nucleophilicity of the second reactive center (the imida-
zole for carnosine and the thiol for penicillamine). By 
contrast, this section will examine those derivatives 
whose quenching activity is almost exclusively deter-
mined by their amino groups. 
 PM (4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-
3-ol; Figure 5), a naturally occurring derivative of vitamin 
B6, has proved to be an eﬀ ective inhibitor for protein gly-
cation and lipoxidation both  in vivo and  in vitro [222]. Its 
protective action involves diﬀ erent mechanism including 
chelation of metal ions with catalytic oxidation capacity 
[56], neutralization of radical species due to the phenol 
acidity [222], and scavenging of carbonyl species with a 
high glycation ability. Recent studies evidenced that PM 
can react with dicarbonyls by rapidly forming stable imine 
derivatives whose stability is enhanced by the low basicity 
of the benzilic amino group as well as by the capacity of 
second carbonyl group to interact with the phenol function 
yielding hemiacetalic cycles [223,224]. Moreover, some 
dicarbonyls can react with two PM molecules yielding a 
dimer fused through a central imidazolium or piperidin-
ium ring depending on the structure of RCS and with a 
mechanism which reminds that of the MOLD adduct start-
ing from two lysine residues [225,226]. Yet again,  γ dicar-
bonyls, which can be derived from alkyl oxidation, rapidly 
cyclize with PM yielding pyrrole derivatives, according to 
Paal – Knorr reaction [227]. Comparative analyses showed 
that PM is more reactive than the  ɛ -amino group of lysine 
residues but remains still less reactive when compared to 
the strong reactivity of a cysteine thiol function [228,229]. 
This means that PM can successfully protect lysine resi-
dues by glycation processes but fails to protect also 
cysteines. Similarly, PM can quench  α , β -unsaturated car-
bonyls by yielding both Michael adducts and imino deri-
vatives which involve the PM amino group [136]. Also 
here, the phenol group can promote these additions by 
yielding the already-mentioned hemiacetalic cycles for 
Michael adducts or condensed hemiaminal rings for 
adducted Schiﬀ  bases [228,229]. The protective eﬀ ects of 
pyridoxime are also reinforced by its enzymatic role since 
the phosphorylation of the hydroxyl group in 5 induces an 
intracellular accumulation through the so-called metabolic 
trapping mechanism [230]. Based on its excellent quench-
ing activities, PM prevented retinal damage [231] and 
improved renal function [232,233] in murine models of 
diabetes and, in contrast to other carbonyl quenchers, such 
as aminoguanidine, PM showed minimal toxicity [234]. 
The promising results of the ongoing clinical studies 
involving PM in diabetes can be found in specialized 
reviews [235]. 
 As mentioned before, diaminopropionic acid (DAP) is 
a residue which possesses a signiﬁ cant reactivity toward 
RCS due to its capacity to give imino adducts. Sasaki and 
coworkers [236] proposed a set of DAP-containing dipep-
tides endowed by a noteworthy capacity to quench AGE 
precursors. Among them, DAP-Val and DAP-Nle showed 
protective eﬀ ects comparable with those of aminoguani-
dine. Interestingly, the prominent reactivity of DAP deri-
vatives toward dicarbonyls was explained by their ability 
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to form stable adducts containing piperazine ring systems. 
Recently, Audic and coworkers reported a set of 2,3-
diaminopropionic acid-based molecules which proved 
to be excellent scavengers of both dicarbonyls and  α , 
β -unsaturated aldehydes. In particular their remarkable 
quenching activity against MDA is ascribable to their 
capacity of yielding stable 2,3-dihydro-1H-1,4-diazepinium 
adducts, as indentiﬁ ed by LC-MS and NMR analyses [237]. 
A similar reactivity is also shown by 2,3 diaminophenazine 
which reduces the formation of AGEs and attenuates the 
diabetes induced vascular hypertrophy with an overall eﬀ ect 
at least comparable to that of aminoguanidine [238]. More-
over, this quencher was also able to increase the collagen 
solubility, a clear eﬀ ect of the inhibition of AGE cross-
linking, whereas it was unable to ameliorate the diabetes-
induced increase in the albumin clearance [239]. 
 Phenols and polyphenols. In the previous section, the 
ancillary reactivity of phenol group in determining the 
marked activity of PM was in-depth analyzed, even though 
the above described molecules cannot clarify whether the 
phenol derivatives possesses enough nucleophilicity to act 
as a carbonyl quenchers  per se [240]. Lo and coworkers 
in a recent systematic study analyzed the quenching acti-
vity of phenols, diphenols, and triphenols evidencing that 
the ﬁ rst two groups are substantially inactive toward MG, 
whereas some triphenols show relevant quenching activity 
not markedly inﬂ uenced by the presence of other substitu-
ents [241]. This ﬁ nding clearly suggests that also natural 
polyphenols can possess eﬃ  cient quenching activities and 
indeed in the last years several natural compounds were 
reported to be able to quench RCS, as recently reviewed 
by Wang [242]. 
 Concerning the capacity of dietary polyphenols to trap 
dicarbonyls, a systematic study [243] with MG showed the 
signiﬁ cant inhibitory eﬀ ects on MG mediated AGEs for-
mation (greater than 60%) for luteolin, rutin, epigallo-
cathin-3-gallate (EGCG), and quercetin, while catechin, 
epicatechin (EC), epicatechin gallate (ECG), epigallocat-
echin (EGC), kaempferol, and naringenin possess lower 
inhibitory eﬀ ects. Among them, theaﬂ avins (Figure 4), the 
main components of black tea, were the most reactive 
polyphenols toward MG with an inhibition eﬀ ect around 
70% thus suggesting that theaﬂ avins would be promising 
candidates for future  in vivo studies [244]. Collectively, 
these studies evidenced the presence of the ﬂ avan-3-ol 
(i.e., catechin) substructure as a key element for the 
quenching activity which is maximized at basic conditions 
and preferentially occurs at positions 6 and 8 of the A-ring 
of catechin while the gallate ring does not play an impor-
tant role in the scavenging activity. Comparative analyses 
showed that the most eﬃ  cient polyphenols are more reac-
tive than lysine and arginine residues thus conﬁ rming their 
protective role against AGE-mediated protein carbonyla-
tion [245]. The chemical relevance of the catechin ’ s A-ring 
in determining carbonyl quenching was substantiated by 
quenching activity of genistein (4 ’ ,5,7-trihydroxyisoﬂ a-
vone; Figure 5) [246], phloretin, and phloridzin [247], 
thus conﬁ rming the major rules proposed by Matsuda and 
coworkers [248], namely that (i) quenching activity 
increases with the number of hydroxyl groups; (ii) ﬂ a-
vones are normally more active than the corresponding 
reduced analogs; (iii) modiﬁ cations of hydroxyl groups 
decrease the activity apart from those on position 3 ’ , and 
(iv) as a rule, there is a relationship between carbonyl 
quenching and free radical scavenging. 
 Even though most studies have been focused on the 
quenching of dicarbonyls by polyphenols, Beretta and 
coworkers demonstrated that green tea polyphenols can 
also trap  α , β -unsaturated aldehydes always exploiting 
the speciﬁ c reactivity of the A-ring despite with a dif-
ferent mechanism. Indeed, while polyphenols quench 
dicarbonyls through an electrophilic substitution in 
which the carbonyl carbon atoms attack the most elec-
tronegative phenyl carbon atoms, unsaturated carbonyls 
react through a Michael addition between a phenol oxy-
gen atom and the acceptor  β carbon atom followed by 
an intramolecular condensation to yield stable benzo-
chromene adducts [249]. 
 Other natural phenolic compounds endowed with 
carbonyl quenching activities toward AGE precursors 
include the stilbene glucosides among which 2,3,5,4- O -
tetrahydroxystilbene 2- O - β -D-glucoside (THSG), the major 
bioactive compound from  Polygonum multiﬂ orum , 
appeared much more active than resveratrol and its methy-
lated derivative pterostilbene, the two major dietary stil-
benes. Similar to ﬂ avones, the quenching occurs through 
an electrophilic substitution involving the electronegative 
positions 4 and 6 of the A ring [250]. Besides the discussed 
polyphenols, also terpenoids [251] and procyanidins [252] 
displayed inhibitory eﬀ ects on AGE formation, which are 
largely ascribable to both their antioxidant activities and 
carbonyl scavenging capacities. Overall, the reported stu-
dies indicate that many natural compounds exert their known 
protective and antioxidant eﬀ ects also through a carbonyl 
quenching activity, and much remains to be done in order to 
elucidate the precise quenching mechanism for these mole-
cules as well as their potential clinical applications. 
 Despite structurally diﬀ erent, also the quenching activ-
ity of ascorbic acid (aka Vitamin C, (5R)-[(1S)-1,2-
dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one; Figure 5) 
can be explained in terms of nucleophilicity of hydroxyl/
enolic functions which act as Michael donor reacting with 
 α , β -unsaturated aldehydes [253]. In detail, ascorbic acid 
reacts with HNE yielding two major adducts, which share 
a common tetrahydrofuro[3,2-b]furan-5-one system and 
diﬀ er from the arrangement of the third tetrahydrofuran 
ring, which is linked in 6 position or fused in a spiro form 
similar to that observed with acrolein (see below [254]). 
Similarly, ascorbic acid can react with acrolein giving a 
tricyclic intermediate which rearranges yielding 5,6,7,
8-tetrahydroxy-4-oxooctanal (THO) which in turn exists 
in solution in equilibrium with the corresponding 5- and 
6-membered cyclic hemiketals and hemiacetals [255]. 
Despite the capacity to generate covalent adducts, the abi-
lity of ascorbic acid to prevent protein carbonylation by 
reactive aldehydes is, however, mostly ascribable to its 
ability to increase the transport of GSH conjugates from 
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the cells into the medium by enhancing the eﬄ  ux of the 
multidrug-resistant protein (MRP) substrate as recently 
demonstrated in human monocytic THP-1 cells [254]. 
 Miscellaneous inhibition mechanisms 
 Anti-inﬂ ammatory drugs. Aspirin was one of the ﬁ rst 
molecules shown to prevent glycation. When present in 
incubations of lens proteins, aspirin inhibited glycation of 
the proteins treated by glucose, galactose, and other sugars 
 in vitro [256 – 258]. Aspirin was classiﬁ ed as a sugar com-
petitor since it acts by acetylation of the reactive amino 
groups on proteins [259 – 261]. Other anti-inﬂ ammatory 
drugs, ibuprofen and diclofenac, also inhibited glycation, 
yet the mechanism may be diﬀ erent since ibuprofen and 
diclofenac have no acetyl group. Aspirin and ibuprofen 
prevented cataract in diabetic rats [262]. 
 Pyruvic acid. The simplest  α -keto acid pyruvate (2-
oxopropanoic acid, an oxidized form of MG) was reported 
to protect rat eye lens proteins against sugar-induced gly-
coxidation [263 – 265] and prevented cataract development 
in diabetic rats or mice. The eﬀ ect was explained by the 
ability of pyruvate to bind competitively to protein pri-
mary amines, as well as by the antioxidant action of the 
compound [264,266]. 
 Aldose reductase inhibitors. Under hyperglycemic condi-
tions, fructose and 3-DG, compounds with high glyca-
tion potential, are produced by the polyol pathway 
[267,268]. Fructose formed via the polyol pathway can 
reach the concentrations same as glucose in certain tis-
sues. In this way, polyol pathway may contribute to the 
process of advanced glycation. The aldose reductase 
inhibitor, epalrestat, was found to reduce plasma levels 
of markers of glycoxidation in diabetic patients [269,270]. 
Epalrestat suppressed the deterioration of diabetic periph-
eral neuropathy in association with a reduction of CML 
blood levels [271]. The aldose reductase inhibitor, zopol-
restat, signiﬁ cantly reduced MG levels in aged rat aorta 
and signiﬁ cantly improved endothelial-dependent relax-
ation in aged rats [272]. 
 ALEs/AGEs elimination 
 Physiological pathways of AGE and ALE removal(NC) 
 Enzymatic defense against AGEs and ALEs 
 Enzymatic deglycation at the Amadori level. Fructosamine-
3-kinase (FN3K) is a key player in the repair of Amadori 
products. It was discovered almost at the same time by 
Delpierre et  al. [273] and Szwergold et  al. [274]. The 
enzyme was puriﬁ ed from human erythrocytes and 
expressed in  Escherichia coli . FN3K is a 35-kDa mono-
meric protein whose tertiary structure is still not resolved, 
even though it should show a certain degree of similarity 
with the recently resolved structure of the putative FN3K 
from  Thermobiﬁ da fusca YX-ER1 (YP_290396.1,
 Pdb Id: 3f7w). FN3K phosphorylates low-molecular mass 
and protein-bound fructosamines on the third carbon of 
the hexose. The enzyme phosphorylates 1-deoxy-1-
morpholinofructose, fructoselysine, fructosevaline, and 
fructoseglycine in order of decreasing aﬃ  nity. Histone, 
bovine serum albumin, lysozyme, or hemoglobin-bound 
fructoselysine was also found to be phosphorylated by 
FN3K. The aﬃ  nity of protein-bound fructoselysines is 
about 75-fold higher as compared with free fructoselysines. 
The reaction of fructoseamine phosphorylation is ATP 
dependent. The phosphorylation product fructosamine-3-
phosphate is unstable and spontaneously decomposes by 
 β -elimination into 3-DG, inorganic phosphate, and non-
glycated amine (Figure 6). As an example, a half-live of 
fructoselysine-3-phosphate is about 5 – 6 h at 37 ° C [274]. 
 The discovery of FN3K in human erythrocytes revealed 
the enzymatic defense mechanism against glycation at its 
early stage. It became obvious that mammalian cells are 
able to prevent further conversion of Amadori products 
into AGEs and to clear fructosamines formed on proteins 
in the cell [275 – 277]. Physiological importance of FN3K 
as a protein repair enzyme was conﬁ rmed in the experi-
ment with FN3K-deﬁ cient mice. Their level of hemoglo-
bin-bound fructosamines was approximately 2.5-fold 
higher than that of control mice. Moreover, other intracel-
lular proteins were 1.8- to 2.2-fold more glycated in eryth-
rocytes and 1.2- to 1.8-fold more glycated in brain, kidney, 
liver, and skeletal muscle [278]. On the other hand, the 
physiological role of FN3K is not fully clear even despite 
the fact that the enzyme is able to reduce the glycation of 
intracellular proteins  in vivo . Recently, it has been shown 
that the survival, functions, and glucotoxic alterations of 
pancreatic  β -cells from both FN3K-knockout and wild-
type mice are almost identical in the presence of high 
glucose concentration [279]. 
 The enzyme is present in mammals and birds, and was 
not found in ﬁ shes, plants, and bacteria [280], even though 
homologous proteins (FN3K-related proteins) are present 
in all taxa, where they retain intracellular repair functions. 
FN3K is particularly active in brain, heart, kidney, and 
skeletal muscle. The activity of FN3K in erythrocytes 
from diﬀ erent species correlates well with the concentra-
tion of glucose. Indeed, FN3K is active in erythrocytes 
from rat, mouse and man where the intracellular concen-
tration of glucose is close to that of the plasma, and the 
activity of FN3K is very low in erythrocytes from pig and 
chicken in which the concentration of glucose is low or 
near zero [281,282]. 
 Besides FN3K, other deglycating enzymes of Amadori 
products are known. In fungi and bacteria, fructosyl amino 
acid oxidases called amadoriases catalyze the oxidative 
degradation of Amadori products leading to the formation 
of unmodiﬁ ed amine and 2-ketoaldose as well as H 2 O 2 . 
In bacteria, fructosamine 6-phosphate deglycases and 
fructoseamine 6-kinases decompose Amadori products, 
although these enzyme use diﬀ erent catalytic mechanisms 
and have diﬀ erent physiological role as compared with 
FN3K [283]. 
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 Enzymatic detoxiﬁ cation of reactive  a -oxoaldehydes. GO, 
MG, and 3-DG are important glycating agents besides 
glucose and fructose (Figure 1). They are up to 20,000-
fold more reactive than glucose and form AGEs bypassing 
the stage of early glycation [284,285]. There are two 
important pathways involved in the enzymatic defense 
against glycation and the prevention of accumulation of 
 α -oxoaldehydes as AGE precursors  in vivo , that is, aldose 
reductase and glyoxalase pathways. 
 Human aldose reductase (AKR1B1; EC 1.1.1.21) 
belongs to the AKR superfamily. AKR are oxidoreductases 
found in organisms from prokaryotes to eukaryotes includ-
ing yeast, plants, amphibia, and mammals. A systematic 
nomenclature for AKR was adopted in 1996. More than 
110 enzymes of AKR superfamily are grouped into 
14 families (AKR1 – AKR14) having less than 40% amino 
acid identity with any other family. Families are divided 
into subfamilies (   60% amino acid identity among mem-
bers) described by a letter, and an Arabic number signs 
the unique protein sequence [286,287]. 
 Human aldose reductase is expressed in almost all tis-
sues [288 – 294]. AKR1B1 is a cytosolic monomeric pro-
tein of 315 amino acids with a molecular mass of about 
36-kDa and known three-dimensional structure. The 
enzyme shows an eight-stranded  β / α -barrel folding and 
catalyzes the NADPH-dependent reduction of a wide 
variety of carbonyl-containing compounds to their corre-
sponding alcohols with a broad range of catalytic 
eﬃ  ciencies [295 – 299]. AKR1B1 is the ﬁ rst enzyme in the 
polyol pathway of glucose metabolism. It catalyzes the 
reduction of glucose to sorbitol that is subsequently 
converted to fructose by sorbitol dehydrogenase. Under 
normal physiological conditions, this pathway plays a 
minor role, and cellular glucose enters the glycolytic path-
way. For aldose reductase, glucose is not a preferred sub-
strate: K M    100 mM and k cat /K M    2.8    10 2 M    1 min    1 
[295]. It seems that the primary role of AKR1B1 is to 
remove reactive aldehydes. Kinetics constants k cat /K M for 
MG, 3-DG, and GO are equal to 1.8    10 7 , 2.5    10 6 , and 
3.0    10 5 M    1 min    1 , respectively. Thus,  α -oxoaldehydes 
are better substrates than glucose as glycating agents lead-
ing to AGEs formation [300,301]. Moreover, the cytopro-
tective role of AKR1B1 against MG was revealed using 
cultured vascular smooth muscle cells. An MG-induced 
dose- and time-dependent increase in aldose reductase 
mRNA accompanied by higher enzyme activity and pro-
tein level was found. However, the cytotoxic eﬀ ect of MG 
was enhanced when the activity of aldose reductase was 
suppressed by ponalrestat, an inhibitor of the enzyme [302]. 
Recently, the  in vivo role of aldose reductase in mammalian 
metabolism of AGE precursors has been studied. The results 
show that the reduction of  α -oxoaldehydes catalyzed by 
aldose reductase is a signiﬁ cant pathway in AGE precursor 
removal in human endothelial cells. Mice aldose reductase 
AKR1B3 is also an eﬃ  cient catalyst for the reduction of 
AGEs precursors. The process is diminished in hearts of 
aldose reductase-null mice. Moreover, diabetic aldose 
reductase  – null mice accumulate more AGEs in the plasma 
and the heart than wild-type mice [303,304]. 
 Cellular metabolism of 3-DG was studied using human 
umbilical vein endothelial cells. The results indicated that 
3-DG was internalized by the cells and reduced to 3-
deoxyfructose by AKRs. The reaction was inhibited by an 
AKR inhibitor [305]. 
 The glyoxalase system consists of two enzymes, glyox-
alase 1 (EC 4.4.1.5) and glyoxalase 2 (EC 3.2.1.6); GSH is 
used as a cofactor. The glyoxalase system catalyzes the 
conversion of  α -oxoaldehydes into the corresponding  α -
hydroxyacids. Glutathione-methylglyoxal hemithioacetal 
formed non-enzymatically from MG and GSH is isomerized 
by glyoxalase 1 to S-D-lactoylglutathione. The latter serves 
as a substrate for glyoxalase 2 and is converted to D-lactate 
and GSH [114,306]. Human glyoxalase 1 is found in all tis-
sues. This is a cytosolic dimeric Zn 2   metalloenzyme of 
molecular mass 42 kDa. For glutathione-methylglyoxal hemi-
thioacetal K M is 71 – 130  μ M and k cat is 7 – 11    10 4 min    1 . 
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 Figure 6. Reaction of fructosamine-3-kinase. 
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Thus, k cat /K M for glyoxalase 1 is approximately 100-fold 
higher than for aldose reductase, thus suggesting that glyox-
alase system should be more eﬀ ective in MG detoxiﬁ cation 
than aldose reductase. Besides MG, physiological substrates 
of glyoxalase are also GO and 4,5-dioxovalerate [307,308]. 
Glyoxalase 2 is also a metalloenzyme and contains a Fe 2   -
Zn 2   center. Zinc plays an essential role in its catalytic 
mechanism. The enzyme has two isoforms and can be 
expressed in cytosol (cytosolic form of molecular mass 29 
kDa) or in mitochondria (the mitochondrial form has molec-
ular mass of 34 kDa). Glyoxalase 2 has a broad substrate 
speciﬁ city for GSH thiol esters. K M and k cat values for S-D-
lactoylglutathione are equal to 146  μ M and 727 s    1 , respec-
tively [308]. The physiological role of the mitochondrial 
isoform is not clear [309]. 
 Some studies show the biological signiﬁ cance of gly-
oxalase system in the enzymatic defense against glycation 
reactions mediated by  α -oxoaldehydes. Shinohara et  al. 
demonstrated that overexpression of glyoxalase 1 in bovine 
endothelial cells reduced intracellular AGEs when the 
cells were exposed to high glucose concentration  in vitro 
[310]. Moreover, the ability of glyoxalase system to reduce 
the level of  α -oxoaldehydes and AGEs was demonstrated 
in an  in vivo model of diabetes. Diabetic transgenic rats 
with a glyoxalase 1 overexpression had less AGEs as com-
pared with wild-type diabetic rats [311]. Glyoxalase 1 is 
also critical for human retinal capillary pericyte survival 
under hyperglycemic conditions. Human retinal capillary 
pericyte incubation with a combination of high glucose 
and bromobenzyl- S - p -glutathione cyclopentyl diester, a 
competitive inhibitor of glyoxalase 1, results in cells apop-
tosis along with an increase in MG concentration. How-
ever, overexpression of glyoxalase 1 in the cells protects 
against apoptosis induced by glyoxalase 1 inhibitor under 
high glucose [312]. Investigations of pathophysiological 
role of glyoxalase 1 in rat renal ischemia-reperfusion 
injury revealed that ischemia-reperfusion induced tubu-
lointerstitial injury and that the histological changes are 
associated with a signiﬁ cant decrease in renal glyoxalase 
activity and an increase in MG level. However, in rats 
overexpressing human glyoxalase 1, renoprotective eﬀ ects 
of that enzyme were observed and the reduction of MG 
accumulation in tubular cells was noticed [313,314]. 
 Glyoxalase 1 expression declines on aging, and oxida-
tive stress results in increased glycation and tissue damage 
[308]. The decrease in the enzyme activity was observed 
in aging human lenses [315], skeletal muscles [316], and 
human brain [317]. In AD, glyoxalase 1 is upregulated in 
a compensatory manner to maintain physiological level of 
 α -oxoaldehydes [318]. However, with advancing stage of 
AD, the decrease in the level of glyoxalase I was observed. 
In both age- and AD-aﬀ ected brains the level of glyoxalase 
1 correlated with AGEs deposits [319]. 
 Intracellular degradation of AGEs by lysosomal 
and proteasomal system 
 Introduction to proteolytic systems. AGEs are the ﬁ nal 
products of the non-enzymatic reaction of reducing sugars 
and reactive aldehydes with amino-groups on macromo-
lecules such as proteins, lipids, or nucleic acids [320,321]. 
These structures are rather stable and capable of forming 
cross-links between proteins. As said above, AGEs have 
been reported to be accumulated during several patho-
logical conditions and have been detected in various foods 
where they are mainly produced by heating [322]. Hence, 
they can be ingested thus promoting clear physiological 
consequences [323]. Among the mentioned strategies to 
reduce their amount  in vivo, the proteolytic catabolism 
requires the precise identiﬁ cation of the enzymatic path-
ways that are involved in the AGE degradation in order to 
modulate them exogenously, thus to increase the cell 
clearance of AGEs. 
 There are two main cellular proteolytic systems that are 
responsible for the degradation of the various macromol-
ecules: the lysosomes and the proteasomes. With regard 
to lysosomal degradation, macromolecules are internal-
ized from the extracellular space by endocytosis and they 
are then transferred by fusion with phagosomes ending up 
in complete degradation by the endosomal – lysosomal sys-
tem. Additionally, cytoplasmic molecules that need to be 
degraded are also processed through autophagy [324]. 
Autophagy can be functionally divided into three known 
pathways including the chaperone-mediated autophagy, 
the macrophagy, and the microphagy. The chaperone-
mediated autophagy is a highly speciﬁ c process where 
substrates to be degraded are unfolded in a chaperon-
assisted process and transported directly into the lyso-
somes via the LAMP-2A membrane channel [325]. Also 
microphagy is a direct uptake into lysosomes, via a not 
very well-understood process of invagination of the lyso-
somal membrane and enclosure of small parts of the sur-
rounding cytosol. In contrast, macrophagy is the new 
formation of a membrane from a starting point. This mem-
brane encircles larger parts of the cytosol, including 
organelles as mitochondria and protein aggregates. Mac-
rophagy is terminated by the complete engulfment of the 
material to be degraded in a structure called autophago-
some, which is later on fusing with lysosomes. It is widely 
accepted that damaged proteins, if not degraded by the 
proteasome, are taken up by macrophagy into the lyso-
somal autosomal compartment. This refers especially to 
protein aggregates, as lipofuscin, and results in the fact that 
only a low percentage of lipofuscin is actually located in 
the cytosol [326]. Interestingly, there seems to be a diﬀ er-
ent approach of cells to sequester protein aggregates: either 
in lysosomes or in aggresomes. While terminally oxidized, 
non-degradable protein aggregates are more located in 
lysosomes [326], while under certain unknown circum-
stances oxidized protein aggregates and AGE-modiﬁ ed 
proteins might be located in aggresomes [327,328]. 
 The proteasome is an important intracellular protease 
complex responsible for the regulated degradation of both 
normal and abnormal proteins. The ubiquitin-proteasome 
system (UPS) and autophagy have long been regarded as 
two separate cellular pathways with distinct functions. It 
was previously thought that autophagy predominantly 
degraded long half-life proteins whereas the clearance of 
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the short half-life proteins that were typical UPS sub-
strates, would not be degraded by autophagy. However, 
studies in the last decade suggest that the two systems 
 “ communicate, ” at least under certain circumstances 
whereas compensatory functions have also been revealed 
in some cases. More speciﬁ cally, concerning modiﬁ ed 
proteins, it has been shown that moderately modiﬁ ed pro-
teins are degradable by the proteasome whereas heavily 
modiﬁ ed proteins are more likely to be processed by the 
lysosomal proteases [329]. 
 Lysosomes. Lysosomes were discovered by Christian de 
Duve and were then recognized as the terminal compart-
ment where the degradation procedure of the endocytic 
pathway occurs. These organelles are highly heteroge-
neous in size and shape, and they are often found to con-
tain electron-dense material and membranous aggregates 
[330]. These single or double membrane organelles pos-
sess various acidic hydrolases, such as peptidases, lipases, 
and nucleases for the degradation of the corresponding 
biological polymers. A proton pump in their membrane 
actively transports protons (H    ions) into the lumen, thus 
maintaining the internal acidic pH that is a prerequisite 
for the optimal activity of hydrolases. These acid hydro-
lases are responsible for degradation of the delivered 
cargo, whereas the derived essential nutrients (amino 
acids, fatty acids, sugars, etc) are then returned to the cyto-
sol through the action of permeases that reside at the 
lysosomal membrane [331]. 
 Brieﬂ y, lysosomal formation is functionally connected 
with endocytic and secretory pathways. Clathrin-coated 
endocytic vesicles are extorted from the plasma membrane 
engulﬁ ng extracellular material. They are then fused with 
early endosomes, and a gradual maturation into late endo-
somes occurs [332]. These late endosomes fuse with trans-
port vesicles, originated from the trans-Golgi network, to 
form the lysosome. The trans-Golgi vesicles have man-
nose-6-phosphate receptors (MPRs) that are necessary to 
attract acid hydrolases. Gradually the internal pH decreases 
to approximately 5 that is characteristic for endosome 
maturation [333]. This pH decrease permits the release of 
acid hydrolases from the MPRs into the lysosomal lumen 
to produce the active lysosomes. At the same time, the 
receptors are recycled back to the Golgi network. 
 Previous work has conﬁ rmed that AGEs undergo 
receptor-mediated endocytosis by various scavenger 
receptors [334]. More speciﬁ cally, several cell surface 
proteins have been identiﬁ ed to recognize and to bind 
AGEs, like the RAGE [335,336], CD36 receptor (belong-
ing to scavenger receptor family type B) [337], mac-
rophage scavenger receptor A I and II (a member of the 
scavenger receptor family type A) [334] and the receptor 
complex p60, p90, and galectin-3 [334,338]. For few of 
them like CD36 [339] and MSR [340], a direct role in 
endocytosis has been shown. Nevertheless, although 
endocytosis of AGEs through speciﬁ c receptors has 
been demonstrated, the proteases that take over to 
degrade the glycated proteins are not fully elucidated. 
However, more and more evidence accumulates that the 
RAGE receptor is just a signaling receptor recognizing 
the presence of AGEs in the extracellular environment, 
but not responsible for the uptake of the material [341]. 
This is clearly the function of the scavenger receptors. 
Miyata et  al. have shown that AGEs-modiﬁ ed proteins 
(in speciﬁ c, pyrraline-modiﬁ ed albumin) accumulate in 
phagocytes under conditions of reduced lysosomal-
mediated degradation, thus implying that the lysosomal 
enzymes are pivotal for the AGE proteolysis [342]. 
Saito et  al. have also conﬁ rmed the endocytic/
lysosomal fate of  125 I-AGE-BSA [343]. More speciﬁ -
cally, they have shown that  125 I-AGE-BSA is less 
degraded following chloroquine and leupeptin addition; 
both agents are known to inhibit the lysosomal enzymes 
function. A similar partial eﬀ ect of lysosomal degrada-
tion has also been suggested to occur in microglial cells 
[344]. Grune and colleagues have identiﬁ ed cathepsin D 
as one of the major enzymes involved in the degradation 
of AGE-modiﬁ ed proteins both  in vitro and  in  vivo 
[345]. More speciﬁ cally, they showed that AGE-
modiﬁ ed albumin is degraded by cathepsin D, while 
cathepsin B is less eﬀ ective in the degradation of 
aldehyde-modiﬁ ed albumin. Additionally, the authors 
suggested that the 20S proteasome was completely unable 
to degrade these modiﬁ ed proteins. With regard to  in vivo 
data, extensive intracellular AGE accumulation was 
revealed in mouse primary embryonic ﬁ broblasts derived 
from cathepsin D knockout animals; these aggregates 
were mainly located in lysosomes. Moreover, in these 
cells, reduced degradation rate of AGE-modiﬁ ed pro-
teins was recorded as compared to the relative levels in 
cells isolated from wild-type animals [345]. More 
recently, along with cathepsin D, the same group has 
also identiﬁ ed cathepsin L to possess a pivotal role in 
the cellular response against AGEs [346]. 
 Grimm et  al. also tested the degradation of AGEs by 
proteases from the gastrointestinal tract. Interestingly, 
pepsin was able to degrade AGE-modiﬁ ed proteins to a 
good extent; however, trypsin and chymotrypsin had a 
lower eﬃ  ciency [345]. It seems that due to the established 
pH optimum of the used cathepsins and the other pro-
teases, in the case of a low pH (perhaps due to the unfold-
ing of the substrate), proteases are able to degrade 
AGE-modiﬁ ed proteins. However, to our knowledge, there 
are no conditions found where AGE-modiﬁ ed proteins are 
degraded with higher eﬃ  ciency compared to the normal 
substrates. In other words, these AGE substrates are not 
degraded preferentially as oxidized proteins in the case of 
the proteasome [347,348]. So it might well be that due to 
the unfolding in the case of a low pH, the protein is just 
degraded, not because it was AGE-modiﬁ ed but regardless 
that it is modiﬁ ed. 
 Aggrephagy. Today, all statements about the fate of 
AGE-modiﬁ ed protein aggregates are highly speculative. 
However, a few wage hints exist, that AGE-modiﬁ ed pro-
teins, if aggregated, might be further processed. First, it 
was shown that AGE-modiﬁ ed proteins, in particular 
AGE-modiﬁ ed vimentin are located in aggresomes [328]. 
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Whether this is a special property of vimentin or important 
for more proteins remains obscure. Since non-modiﬁ ed 
vimentin is a part of the aggresome caging structure [349], 
it might well be that vimentin is  – modiﬁ ed or not  – targeted 
to aggresomes, once they are formed. However, since 
aggresomes in general sequester proteins which are not 
degraded eﬃ  ciently by the UPS, also AGE-modiﬁ ed pro-
teins, might be targeted toward aggresomes. In general, 
aggresomes are known to be ubiquitinated  in vitro and 
 in vivo [350]. Interestingly, it was more recently detected 
that ubiquitination of aggresomes happens as well in the 
K48, K63, and K11 positions of the ubiquitin [351]. In 
particular, the K63-lysine binding of ubiquitin draws the 
attention of researchers, since this kind of ubiquitination 
is targeting for autophagy-mediated lysosomal degrada-
tion [352]. This gave hints that aggregated proteins at 
least if packed in aggresomes might be targeted toward 
autophagy. This process is referred to as  “ aggrephagy ” . 
Of special interest is, of course, the recognition of the 
aggresome during the initial steps of autophagy. It is gen-
erally acknowledged that aggrephagy is a special form of 
macrophagy. The process of aggrephagy is until now not 
well understood, but it is known already that a wealth of 
regulatory proteins are playing a role, including HDAC6, 
p66, NBR1, mTOR, and Alfy, just to name a few. For an 
extensive review of aggrephagy, see [353]. 
 To conclude, it should be mentioned that the targeting 
of AGE-modiﬁ ed protein aggregates toward the lysosomes 
does not mean that lysosomal proteases are able to degrade 
the uptaken material completely. Most studies reporting 
the degradation of aggregates/aggresomes targeted to lys-
osomes refer to just unfolded proteins, but not to modiﬁ ed 
proteins or AGE-modiﬁ ed proteins [353]. 
 Proteasomes. The proteolytic core, the 20S proteasome, is 
a 700-kDa multisubunit enzyme complex composed by 7 
diﬀ erent  α - and 7 diﬀ erent  β -subunits. The subunits of the 
same type form heptameric rings; thus, two  α - and two 
 β -type rings give rise to the barrel-shaped proteasome. 
The ﬁ nal structure of the proteasome is the  α 1 – 7 β 1 – 7 β 1 – 7 α 1 – 7 structure [354,355]. Three of the  β -subunits,  β 1 , 
 β 2 , and  β 5 , are responsible for the proteasome-hydrolyzing 
activities that cleave peptide bonds on the carboxyl site of 
acidic (peptidylglutamylpeptide-hydrolyzing or caspase-
like activity, PGPH or C-L), basic (trypsin-like activity, 
T-L) and hydrophobic (chymotrypsin-like activity, CT-L) 
amino acids, respectively [356]. The N-terminal threonine 
residues of these active  β -type subunits act as nucleophiles 
during hydrolysis, thus forming the catalytic centers of the 
complex. In mammals, upon speciﬁ c conditions, the con-
stitutively expressed  β 1,  β 2, and  β 5 subunits can be sub-
stituted during  de novo proteasome biosynthesis by the 
immunosubunits, namely  β 1i,  β 2i, and  β 5i, thus forming 
the immunoproteasome [357]. Immune and non-immune 
functions have been attributed to this special proteasome 
type [358], but most importantly, the immunoproteasome 
has been demonstrated to conduct the eﬃ  cient turnover of 
oxidatively damaged proteins and thus to reduce the 
formation of harmful protein aggregates [359,360]. 
Additional regulatory complexes can be attached at the 
ends of the 20S core, thus giving rise to various protea-
some supra-complexes with the 26S proteasome being the 
most known (two 19S regulatory complexes that bind 
either to one or both ends of the 20S core) [356]. Con-
trolled protein degradation is predominately catalyzed by 
the proteasome. Therefore, this complex is responsible for 
cell clearance of abnormal, denatured or, in general, dam-
aged proteins as well as for the regulated degradation of 
short-lived proteins [356,361]. 
 Regarding the proteolysis of AGEs by the proteasome, 
Grimm et  al. have demonstrated that although the 20S 
proteasome is able to degrade oxidized BSA, it is com-
pletely inert to degrade AGE-modiﬁ ed albumin [345]. 
More speciﬁ cally, they clearly showed that although 
AGEs could be degraded by cathepsin D, they could not 
be aﬀ ected by the proteasome. This study is in accor-
dance with the study of Bulteau et  al. who have demon-
strated that CML, a known AGE structure, is resistant to 
the 20S proteasome degradation [362]. In contrast, acti-
vation in terms of both content and activities of nuclear 
proteasomes and degradation of carboxymethylated his-
tones was reported in human keratinocytes following 
GO treatment [363]. Stolzing et  al. have suggested that 
microglial cells are able to degrade BSA-AGEs both 
through lysosomal and also through proteasomal path-
ways [344]. A functional interaction between both lyso-
somal and UPS-mediated degradation was also shown in 
both live cell and cell-free systems by Taylor and col-
leagues [364]. Finally, a recent study has shown that 
AGEs induce the expression of immunoproteasomes 
[346]. More speciﬁ cally, AGEs inhibited the activities of 
the constitutive proteasomes and promoted the decrease 
in the expression of the constitutive  β -type subunits, 
while they increased both expression and activities of 
immunoproteasomes. This induction involved in the acti-
vation of RAGE and the downstream modulation of Jak2/
STAT1 [341]. Although the authors have not checked 
whether the increased immunoproteasome function leads 
to increased clearance of AGEs, one cannot rule out the 
possibility that immunoproteasomes may degrade AGEs 
instead of constitutive proteasomes that have been tested 
up to now. However, it seems that the AGE degradation 
by the immunoproteasome if happens at all is a slow, 
non-eﬃ  cient process. Finally, it is noteworthy that regard-
less of the negative or the positive eﬀ ect of the protea-
some-mediated degradation on the AGEs-modiﬁ ed 
proteins, the majority of these studies report that these 
proteins additionally reveal a deleterious eﬀ ect on the 
proteasome function mainly through its inhibition [344,
363,365]. 
 Strategies to activate the proteasome (NC) 
 20S complex modulation 
 Given that it is still debatable whether the proteasome 
(constitutive or immunoproteasome) is involved in the 
degradation of AGEs, a potential induction of the 
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proteasome would be interesting in case the AGEs are 
ﬁ nally shown to be degraded by the proteasome. Never-
theless, although the proteasome biology is highly inves-
tigated, the existing knowledge with regard to activation/
upregulation of the proteasome is still limited [354,366]. 
There are few studies in the literature dealing with protea-
some activation through genetic manipulation of the 20S 
proteasome core subunits or through the use of natural or 
synthetic compounds [367]. 
 Genetic manipulation of the proteasome 
 With regard to genetic manipulation of the 20S protea-
some, it has been shown that overexpression of  β 5i subunit 
in lymphoblasts and HeLa cells promotes enhancement 
of cleavage after hydrophobic amino acids (CT-L activity) 
and basic amino acids (T-L activity) while enhancement 
of the basic activity (T-L) was also recorded upon trans-
fection of the  β 1i subunit [368]. With regard to overex-
pression of a constitutive catalytic subunit, overexpression 
of  β 1 subunit in HeLa cells was shown to stimulate the 
acidic activity (PGPH or C-L) [369]. We have also shown 
that upon overexpression of the constitutive  β 5 catalytic 
subunit either in WI-38/T and HL60 cells or in human 
primary ﬁ broblasts (IMR90), new and functional protea-
somes are produced. In the presence of these enhanced 
levels of proteasomes, the cells exhibit higher rates of 
proteolysis following treatment with various oxidants, 
they possess an enhanced capacity to cope with stress 
and to survive, and they have decreased levels of 
oxidized proteins. Moreover, upon  β 5 transfection in 
primary human embryonic ﬁ broblasts (IMR90 cells), an 
 ~ 15 – 20% life span extension is recorded [370]. Similar 
proteasome modulation has been also produced through 
 β 5 transfection in lens epithelial cells [371] and murine 
neuroblastoma cells [372]. On top of that, upon upregu-
lation of the levels of proteasome subunits through 
genetic manipulation in aged human ﬁ broblasts, the lev-
els of various aging biomarkers were markedly reduced 
[373]. Accordingly, proteasome activation has been suc-
ceeded genetically through overexpression of: a) hUMP1/
POMP in human ﬁ broblasts [374], and b) UMP1 in yeast 
[375], the necessary chaperones for  β -ring formation 
during proteasome assembly [376,377]. Rpn4 transcrip-
tion factor in yeast has been shown to be responsible for 
the transcription of most proteasome genes [378], thus 
regulating the homeostasis of the yeast proteasome [379] 
and its response under stress conditions [380]. It was 
recently shown that Rpn4 manipulation can also lead to 
proteasome activation and thus to extension of the repli-
cative life span of  S. cerevisiae and to improved clear-
ance of toxic huntingtin fragments in the relative yeast 
model for neurodegenerative diseases [381]. In total, 
these studies support the pivotal role of the proteasome 
activation in the retardation of senescence. Given that 
AGEs have been also shown to increase with aging and 
senescence, proteasome activation in aged cells could 
accordingly has increased signiﬁ cance in AGEs elimina-
tion through degradation. 
 Compound-mediated proteasome activation 
 Given that there are ethical restrains of any manipulation 
in humans, the interest of scientists and companies has 
been turned recently into the identiﬁ cation of natural or 
synthetic compounds with proteasome-activating proper-
ties. It was initially shown that this activation is feasible 
through the  “ opening ” of the closed/latent structure of the 
proteasome and thus through conformational changes. 
Proteasome activities were shown to be stimulated in the 
test tube upon the addition of SDS or fatty acids such as 
olein, linoleic, and linolenic acids [382,383], in contrast 
to the inhibition of these activities in the presence of 
potassium chloride that seemed to promote the latent form 
of the complex [384]. Similar activating properties have 
also been exhibited by hydrophobic peptides that were 
bound as modiﬁ ers at non-catalytic sites and opened the 
 α -gated pore of the 20S complex, thus mimicking the 
action of the 11S complex [385]. Synthetic peptidyl alco-
hols,  p -nitroanilides, esters, and nitriles along with cellu-
lar lipid components such as lysophosphatidylinositol, 
ceramides, and cardiolipin were also reported to activate 
the proteasome through binding to the 11S-complex-
binding site [386 – 389]. More recently,  S -glutathionylation 
was also reported to constitute a post-translational modi-
ﬁ cation that triggers gate opening and, thus, proteasome 
activation, whereas following treatment with high concen-
trations of dithiothreitol, the gate was closed [390]. We 
have also identiﬁ ed oleuropein, a phenolic compound in 
 Olea europaea leaf extract, olive oil, and olives, as a 
potent stimulator of proteasome activities  in vitro. Human 
primary ﬁ broblasts treated with oleuropein were also more 
resistant to oxidative stress and exhibited extended cellular 
life span [391] . We have suggested that oleuropein most 
likely alters the conformation of 20S  α -gated channels 
reminiscent to the SDS action. Similar stimulatory eﬀ ects 
on 20S proteasome activities and thus protective outcomes 
were also described for a lipid algae extract ( Phaeodactylum 
tricornutum) in human keratinocytes following UVA and 
UVB irradiation [392]. Finally, betulinic acid, a pentacy-
clic triterpene, has also been shown to act as a proteasome 
activator only enhancing the CT-L proteasome activity 
[393], while recently lithocholic acid derivatives 3 α - O -
pimeloyl-lithocholic acid methyl ester and its isosteric 
isomer were also identiﬁ ed as activators of the chy-
motrypsin-like activity [394]. 
 The above-mentioned studies investigated compounds 
that are mainly interfering with the structure of the 20S 
complex with a consequent induction of its activities. Nev-
ertheless, several exogenous stimuli have been shown to 
modulate the expression of proteasome subunits and the 
relative activities in mice through the regulation by nuclear 
factor (erythroid-derived 2)-like 2 (Nrf2). This transcrip-
tion factor has been shown to be induced in response to 
antioxidants such as 3H-1,2-dithiole-3-thione (D3T) [395] 
or sulforafane [372], thus promoting the expression of 
cytoprotective genes and the downstream elevated protec-
tion against various oxidants. More speciﬁ cally, Nrf2 has 
been suggested as a guardian of healthspan and gatekeeper 
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of species longevity [396]. Nrf2 belongs to the family of 
Cap ’ n ’ collar (Cnc) transcription factors, and it is the 
central mediator of a prominent antioxidant response 
system by orchestrating the transcriptional response of 
cells to oxidative stressors and electrophilic xenobiotics. 
The genes that are included in the list of Nrf2 target 
genes encompass multiple phase 2 genes, such as GST, 
 γ -glutamylcysteine ligases, heme-oxygenese 1 (HO-1) and 
NADPH quinone oxidoreductase [397], molecular chap-
erones and proteasome subunits [395]. The regulation 
occurs through a common DNA regulatory cis-acting 
element, called antioxidant response element (ARE) or 
electrophile responsive element (EpRE; 5 ’ -TGA[C/T]
NNNGC-3 ’ ) [398]. The main regulator of Nrf2 is the 
Kelch-like ECH-associated protein 1 (Keap1) that carries 
multiple cysteine residues that are oxidatively modiﬁ ed 
according to the changes in the intracellular redox state 
[399]. Under non-stimulated conditions, Nrf2 is bound by 
Keap1 and thus sequestered in the cytoplasm while it is 
actively targeted for ubiquitination and proteasomal deg-
radation [400]. Moreover, Nrf2 may became phosphory-
lated and/or Keap1 may be modiﬁ ed/phosphorylated 
[401], resulting in the disruption of the Keap1 – Nrf2 com-
plex and the nuclear translocation of Nrf2 [402]. Once 
transferred into the nucleus, Nrf2 heterodimerizes with a 
small musculo-aponeurotic ﬁ brosarcoma (MafF, G, or K) 
protein, thus forming a heterodimer that binds to AREs of 
the target genes to stimulate their expression [403,404]. 
Several chemopreventive agents and natural compounds 
have been reported as potent Nrf2 inducers at low doses. 
D3T, sulforaphane, curcumin, lycopene, carnosol, querce-
tin, epigallocatechin-3-gallate, resveratrol, and wasabi are 
included in this list [405,406]. Nevertheless, the interac-
tion with the proteasome has only been investigated for 
few of them [372,395]. Two triterpenoids namely heder-
agenin and 18 α -glycyrrhetinic acid have been identiﬁ ed 
by our group as potential Nrf2 indu cers. Treatment of 
human primary ﬁ broblasts with 18 α -glycyrrhetinic acid 
resulted in Nrf2 activation and the downstream protea-
some induction in terms of RNA and protein expression 
levels as well as in terms of proteasome activities. These 
increased levels of proteasome function coincided with 
increased stress resistance and cellular life span extension. 
These positive outcomes are dependent on the Nrf2-me-
diated proteasome activation since inhibition of the pro-
teasome induction abrogated the enhanced cell survival 
despite the presence of the compound [407]. We have also 
shown elevation of CT-L proteasome activity and induc-
tion of the proteasome content upon treatment of HFL-1 
human primary cells with quercetin [408], a known Nrf2 
enhancer [409]. Given that genes of the 26S proteasome 
complex have been shown to be regulated by Nrf2 [395], 
the observed quercetin-mediated proteasome activation 
could be Nrf2 mediated. Constant treatment of cells with 
quercetin leaded to enhanced cellular life span [408] while 
similar life span-extending results were also observed 
upon feeding of  C. elegans with quercetin [410,411] with-
out, however, investigating a possible link with protea-
some induction. On top of the above studies regarding the 
cross talk between the proteasome and Nrf2, it has also 
been shown that Nrf2 is activated by lipid peroxidation 
end products (e.g., 4-hydroxynonenal (HNE)) [412], thus 
further linking the Nrf2 signaling pathway with the 
response to diﬀ erent types of modiﬁ ed proteins. 
 Cross-link breakers (GA) 
 Collagens and elastin are cross-linked in a tightly regu-
lated manner by the copper-containing quinoprotein lysyl 
oxidase (enzymatic cross-linking), and these bonds pro-
vide mechanical strength and confer resistance against 
non-speciﬁ c proteases [413]. In contrast to this speciﬁ c 
enzymatic oxidation, non-enzymatic cross-linking is not 
selective and may aﬀ ect the structure and function of 
ﬁ brillar collagen and extracellular matrix, causing vascu-
lar and myocardial stiﬀ ness: this leads to elevated systolic 
and pulse pressures, impaired ventricular relaxation, and 
diastolic dysfunction [414]. Once formed, non-enzymatic 
cross-links are highly resistant to proteolysis degradation 
and they apparently inhibit activation of matrix metallo-
proteinase (MMP) thereby promoting collagen accumula-
tion and ﬁ brosis [415]. Non-enzymatic cross-linking of 
collagen is mainly due to glycation and to other covalent 
modiﬁ cations induced by RCS, forming irreversible AGE 
and ALE adducts, including glyoxal – lysine dimer (GOLD), 
methylglyoxal – lysine dimer (MOLD), glyoxal-derived 
imidazolium cross-link (GODIC), lysine-arginine cross-
links derived from glucose (GLUCOSEPANE), and MG-
derived imdazolium cross-link (MODIC)(Figure 7). Of 
these, GLUCOSEPANE, GODIC, and MODIC have been 
recognized as being the most important  in vitro and 
 in vivo , although the molecular steps by which they arise 
are uncertain [416 – 418]. Recently, the cross-linking 
mechanisms of GO and MG with lysine and arginine have 
been studied using a molecular modeling approach. One 
proposed route involves the formation of an aldimine 
(Schiﬀ  base) by reaction of GO or MGO with lysine, fol-
lowed by reaction with the guanidine group on the side 
chain of an arginine residue. The reaction ﬁ nishes by some 
rearrangement and proton transfer reactions that lead to 
the cross-linked product [419]. 
 It is quite clear that inhibitors of AGEs/ALEs as 
reported in 2.1 cannot aﬀ ect preexisting cross-linking. 
The ﬁ rst study on a rational design of AGEs breakers 
was published in 1996 by Vasan et  al. [420]. The strategy 
was based on the design of compounds able to covalently 
react and then cleave the  α -dicarbonyl derivatives which 
were proposed as intermediates of AGEs formation. The 
prototype was identiﬁ ed as N-phenacylthiazolium (PTB), 
and the proposed reaction mechanism is reported in 
Figure 8, consisting of the covalent adduction of the 
thiazolium ring to the dicarbonyl intermediate to form a 
condensed thiazolium intermediate which rearranges to 
regenerate the AGE breaker and leaving the CML moiety 
on a peptide fragment and the aldehydic function on the 
other peptide involved in the cross-link. Further studies 
on PTB were discontinued due to the chemical instabi-
lity of the compound, undergoing a rapid hydrolysis at 
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pH 7.4 (k Hydrolysis was 2.6    0.1    10    4 s; half-life ca. 
44 min), forming two isomeric 2,3-dihydro-4-formyl-2-
hydroxy-2-phenyl-1,4-thiazines [421]. Stabilization of 
the thiazolium ring was obtained by inserting two methyl 
groups, leading to the stable 4,5-dimethylthiazolium 
derivative and named ALT-711 or Alagebrium (N-
phenacyl-4,5-dimethyl-1,3 thiazolium bromide) [422]. 
ALT-711 represents the lead compound of this class and 
several studies have been thus far reported, showing the 
eﬀ ects of ALT-711 in diﬀ erent animal models as well as 
in clinical trials in reversing the cardiovascular compli-
cations of aging and diabetes. ALT-711 was ﬁ rstly 
reported by academic researchers and was then devel-
oped by Alteon Corporation which changed its name to 
Synvista Therapeutics, Inc. The company seems to have 
discontinued operations, and the clinical trials were ter-
minated early in 2009 as reported in the clinicaltrial.gov 
web site due to ﬁ nancial constraints. The web site of the 
company is no longer available. 
 Belonging to the class of thiazolium AGE breakers, two 
derivatives coded C16 [423] and C36 [424], which were 
found to be as eﬀ ective as ALT-711 in animal models, but 
exhibiting lower LD50 in mice and neither mutagenesis 
nor teratogenesis in  ex vivo studies. More recently, a novel 
class of AGE breakers has been reported by Torrent 
Research Centre and characterized by a pyridinium (PMT) 
ring. TRC4186 and TRC4149 are the chloride and bro-
mide salts, respectively, of the same novel active base, 
PMT, 3-[[2-(methylsulfonyl) hydrazino] carbonyl]-1-[2-
oxo-2-2-thienyl) ethyl] (PMT) [425]. The compounds 
have demonstrated AGE-breaking activities in  in vitro 
experiments improving the endothelial and myocardial 
functions in animal models of diabetes mellitus with 
reduction of AGEs accumulation in tissues over time. A 
phase I clinical study of TRC4186 was carried out to 
evaluate the safety, tolerability, and pharmacokinetics 
of TRC4186 in healthy human subjects after single and 
multiple ascending doses, ﬁ xed doses in elderly male and 
female subjects, and with food and diﬀ erent formulations 
of the compound [426]. 
 While the AGE breakers have been found to exert 
beneﬁ cial eﬀ ects and, in particular, to increase vascular 
elasticity, and to improve cardiovascular functions in 
aging humans, in animal models of diabetes, and in other 
diseases, several questions remain unanswered regarding 
the real mechanism of action, as recently pointed out by 
Nagai et  al. [427]. The AGE breakers have been designed 
to react with the dicarbonyl intermediates of AGEs but, 
as noted by Nagai et  al. [427], not a single cross-link 
structure identiﬁ ed in tissue proteins to date contains a 
dicarbonyl structure susceptible to the proposed mecha-
nism of action. Indeed, the proposed target of AGE 
breakers, the dicarbonyl compounds, would be too reac-
tive to accumulate. 
 In model systems, the AGE breakers were tested with 
phenylpropanedione (PPD), a model for putative dicarbo-
nyl cross-links in tissue proteins, and the cleavage product, 
benzoic acid, was readily measured by reversed-phase 
HPLC. However, when the AGE breakers were applied to 
cross-linked proteins, isolated from diabetic animals, the 
AGE breakers were found to be ineﬀ ective and this is eas-
ily explained by considering that the well-recognized AGE 
cross-links detected in tissue proteins including pentosi-
dine, crosslines, vesperlysines, ﬂ uorolink, GOLD, MOLD, 
and GLUCOSEPANE, which, based on their structures, 
would not be susceptible to cleavage by AGE breakers 
[428]. Similar results were obtained by [429], reporting 
that treatment with PMT did not reverse the cross-linking 
of rat skin and tail collagen, cross-linked by incubation 
with glucose or ribose  in vitro . 
 The beneﬁ cial eﬀ ect of the AGE beakers so far reported, 
which is not questionable and conﬁ rmed by several 
research groups, could be ascribed to alternative mecha-
nisms as pointed out by Nagai et  al. [427]. For instance, 
 Figure 7. Structures of Lys – Arg (panel A) and Lys – Lys cross-links (panel B). 
Fr
ee
 R
ad
ic
 R
es
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ita
 S
ta
ta
le
 M
ila
no
 o
n 
01
/2
7/
14
Fo
r p
er
so
na
l u
se
 o
nl
y.
  Preventing glycoxidation and lipoxidation  113
PTB and ALT-711 have been reported to act as metal ion-
chelating agents and their hydrolysis products have even 
stronger chelating properties than the intact compounds 
[430]. Moreover, it should be noted that the AGE breakers 
designed to react with the dicarbonyl protein AGEs inter-
mediates are also eﬀ ective quenchers of MG [431,432] 
and possibly other dicarbonyl compounds which are well-
recognized AGE precursors. In conclusion, although the 
AGE breaking mechanism is very promising since it 
would permit the recovery of oxidized proteins, the ben-
eﬁ cial eﬀ ects of the so-called AGE breakers are unlikely 
to be the result of cleavage or reversal of preexisting AGE 
cross-links. It is more likely that AGE breakers may have 
more direct eﬀ ects on the formation of AGEs through 
their antioxidant and chelating eﬀ ects and their reaction 
mechanism with MG and other dicarbonyl intermediates 
in the Maillard reaction. 
 AGE and ALE clearance (MS) 
 Lysozyme, an antimicrobial enzyme with the ability 
to mediate degradation of the peptidoglycan component 
of bacterial wall, was shown to bind AGEs with high 
selectivity and aﬃ  nity [433]. Lysozyme administration 
decreased circulating AGE levels and enhanced renal 
AGE excretion [434]. The AGE-binding properties of 
lysozyme have been used to reduce AGE levels in the 
dialysate from diabetic patients with kidney disease [435]. 
Oral administration of microencapsulated lysozyme 
decreased serum levels of AGEs and attenuated neph-
ropathy in STZ diabetic rats [436]. Overexpression of the 
native lysozyme in transgenic mice was found to protect 
against acute oxidative stress and to confer resistance to 
chronic oxidative stress against milder oxidants, such as 
AGEs, with a subsequent reduction in vascular cell 
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 Figure 8. Structure of AGEs breakers (lower panel) and proposed reaction mechanism of thiazolium-derived AGEs breakers (upper panel). 
The simpliﬁ ed reaction mechanism is referred to the dinucleophilic attack of the thiazolium ring toward the dicarbonyl AGE cross-link 
followed by internal rearrangement and hydrolysis. 
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inﬂ ammation and proliferation [437,438]. Under  in  vitro 
conditions, lysozyme was found to bind more eﬃ  ciently 
to AGE-modiﬁ ed low-density lipoprotein (LDL), increased 
in type 2 diabetic patients, than to unmodiﬁ ed LDL [439]. 
 Inhibition of absorption of dietary AGEs may be a 
novel approach to reduce the deleterious eﬀ ects of AGEs. 
AST-120 (Kremezin) is an oral adsorbent that attenuated 
the progression of chronic renal failure by removing ure-
mic toxins, including AGEs [440 – 442]. As reported by 
Hayashino et  al., treating type 2 diabetic patients with 
AST-120 slowed the progression of the end-stage renal 
disease [443]. Long-term treatment with AST-120 was 
found beneﬁ cial for chronic renal failure patients in the 
predialysis stage [444]. 
 Reducing exogenous exposure (MS) 
 AGEs are not only generated endogenously under hyper-
glycemic conditions but also derived exogenously from 
AGE rich meal. Diet is a major environmental source of 
AGEs with the highest yield in foods rich in carbohy-
drates and fats [445]. Formation of AGE is enhanced by 
exposure to heat. According to Sgarbieri et  al. and 
Koschinsky et  al., an estimated 10% of AGEs ingested 
are absorbed into the body ’ s circulation, and two-thirds 
of those absorbed are retained [446,447]. Numerous stu-
dies in animals and humans have conﬁ rmed the substan-
tial toxic role of exogenous AGE derivatives in multiple 
target systems, as reviewed by Huebschman et  al. [448]. 
For example, mice on high AGE diet exhibited signiﬁ cant 
albuminuria and glomerular sclerosis, eﬀ ects not seen in 
mice fed with low AGE diet [449]. A clinical study by 
Uribarri et  al. showed that restriction of dietary glycotox-
ins reduced excessive AGEs in renal failure patients 
[445]. These observations suggest that restriction of 
food-derived AGEs or inhibition of absorption of dietary 
AGEs may also be a target for therapeutic anti-AGE strat-
egy [445,448,450 – 454]. 
 Blockade of the ligand – RAGE axis (GB) 
 Studies of several last decades demonstrated that a sig-
niﬁ cant part of oxidative stress in cells exposed to prod-
ucts of glycoxidation is due to the stimulation of special 
receptors present on cell surface, namely RAGE. 
 RAGE 
 This protein is a multiligand transmembrane receptor, 
which was originally identiﬁ ed as a receptor for the het-
erogeneous AGE [455]. RAGE is expressed in several 
cells including endothelial, smooth muscle cells, and neu-
rons, at a very low level in physiological conditions but at 
higher levels during embryonic development. This sug-
gests that RAGE signaling may play an important role 
during development, although deletion of RAGE does not 
result in fertility disturbances or overt phenotypes except-
ing hyperactivity and increased sensitivity to auditory 
stimuli in mice [455 – 457]. RAGE being also involved in 
tissue homeostasis and regeneration/repair upon acute 
injury, and in resolution of inﬂ ammation [458,459]. Con-
ditions such as diabetes and atherosclerosis lead to over-
expression of RAGE [460]. Final eﬀ ects of RAGE axis 
activation include endothelial dysfunction, activation of 
coagulation, and increase in the activity of the renin – 
angiotensin system [461]. RAGE-overexpressing diabetic 
mice show progressive glomerulosclerosis with renal dys-
function, compared with diabetic littermates lacking the 
RAGE transgene. Diabetic homozygous RAGE null mice 
fail to develop signiﬁ cantly increased mesangial matrix 
expansion or thickening of the glomerular basement mem-
brane. Taken together, these ﬁ ndings suggest that the acti-
vation of AGE – RAGE axis contributes to the expression 
of VEGF and enhanced attraction/activation of inﬂ amma-
tory cells in the diabetic glomerulus, thereby setting the 
stage for mesangial activation and TGF-beta production 
[462]. RAGE has also a pro-adipogenic function in senes-
cent preadipocytes by suppressing p53 function, which 
may contribute to aging-dependent adiposity by glycated 
proteins derived from the diet and/or chronically dysregu-
lated metabolic conditions such as hyperglycemia [463]. 
 RAGE ligands fall into several distinct families. They 
include the high-mobility group family proteins including 
the prototypic HMGB1/amphoterin, members of the S100/
calgranulin protein family, matrix proteins such as colla-
gens I and IV, amyloid  β peptide, some AGEs such as 
CML, and phosphatidylserine. The S100/calgranulin 
family consists of closely related calcium-binding poly-
peptides, which act as proinﬂ ammatory extracellular 
cytokines. Not all members of these families have been 
identiﬁ ed as RAGE ligands, and many RAGE ligands have 
a variety of RAGE-independent eﬀ ects. AGEs, which rep-
resent the ﬁ rst RAGE ligand discovered in the 90s, are 
prevalent in pathological conditions marked by oxidative 
stress, generation of methoxyl species, and contribute to 
the increase in blood sugar level, as found in type 2 dia-
betes mellitus [456,458,460]. 
 RAGE has been described as a pattern recognition 
receptor, able to recognize a common pattern within its 
diﬀ erent ligands. RAGE ligands do not seem to share 
much similarity. Nevertheless, all have a net negative 
charge at neutral pH: S100 proteins are very acidic, AGE-
modiﬁ ed proteins accumulate negative surface charge 
during their transformation by glycation and oxidation, 
amyloid  β -peptide has a net negative charge, and amyloid 
ﬁ brils expose a regular pattern of negative charges on 
their surface, while HMGB1 contains a highly acidic 
domain. Phosphatidylserine is also negatively charged at 
physiological pH. The second common feature is the ten-
dency of most RAGE ligands to oligomerize [464]. The 
interactions contributing to this eﬀ ect include also hydro-
phobic regions of the not charged and lipophilic AGEs. 
AGEs are negatively charged as the result of the Maillard 
formation reaction, by which reducing sugars or alde-
hydes modify arginines and lysines to produce glycated 
proteins, adding a net negative charge on the proteins at 
physiological pH. AGE binding to the V region of RAGE 
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is initially facilitated by the ionic attraction between the 
positive charges of RAGE and the negative charges of 
AGE. The binding complex is then stabilized with hydro-
phobic interaction after conformational changes. It is not 
still well understood, which among the diﬀ erent AGEs 
products so far identiﬁ ed act as a binder of RAGE, which 
is the order or aﬃ  nity, nor whether ALEs, such as HNE 
or MDA protein adducts also bind RAGEs. In fact, with 
the exception of CML and CEL generated in a peptide or 
protein environment, most of the studies so far reported 
on RAGE activation by AGEs are based on not structur-
ally resolved AGEs which are usually generated by incu-
bating proteins (very often albumin) with glucose or 
fructose or with GO/MG resulting in the formation of a 
diﬀ erent set of glycoxidation products, spanning from 
either early glycation to cross-linking products, depend-
ing on the incubation times [465]. 
 RAGE consists of an extracellular region, which is 
composed of one ligand-binding V-type Ig domain and 
two Ig-like C-domains (C1 and C2), a short hydrophobic 
transmembrane-spanning region, and a signal-transducing 
cytoplasmic domain. The V and C1 domains form an inte-
grated structural unit (VC1), which is involved in the 
ligand recognition. The V domain is characterized by at 
least two distinct regions involved in the ligand engage-
ment. In particular, X-ray and NMR studies have revealed 
the presence of a large hydrophobic region together with 
a positively charged region on the surface of the V-
domain. The former is involved in the hydrophobic inter-
actions, and the latter in the electrostatic bindings, as those 
involved with the negative charged sites of the ligands. As 
a matter of fact, the exact molecular interactions of RAGE 
with its ligands are still far from being elucidated, and this 
is particularly true in the case of AGEs. The lack of infor-
mation on AGE – RAGE interaction is in part due to the 
fact that AGEs are an heterogeneous class of oxidized 
products where the chemical variability is not only referred 
to the oxidized moiety such as CML, CEL, and methylg-
lyoxal-hydroimidazolone (MGH-1), but also to the sur-
rounding chemical environment, which is also required for 
the RAGE interaction. In fact, it has been found that CML 
and CEL do not bind RAGE as such, but only when they 
are embedded in a peptide or protein, suggesting that both 
the oxidized moiety and the surrounding backbone are 
required for RAGE interaction. Hence, the oxidized moi-
ety of AGEs represents a necessary but not suﬃ  cient con-
dition for the RAGE recognition [459,464]. 
 The ligand – RAGE engagement induces the activation 
of multiple signaling pathways that may vary depending 
on the nature of the ligand and on the cell and tissue 
microenvironment, thus mediating diﬀ erent cellular 
responses. For example, the RAGE activation by AGEs 
induces NADPH oxidase activation leading to ROS for-
mation which on the one hand further propagates the 
oxidative damage and hence the AGEs production. 
Another eﬀ ect is the NF κ B activation which promotes an 
increased gene transcription of pro-inﬂ ammatory and 
pro-ﬁ brotic cytokines and chemokines leading to an 
inﬂ ammatory condition [455]. The diversity of signaling 
cascades identiﬁ ed in RAGE-mediated cellular signaling 
implies that diﬀ erent RAGE ligands might induce diﬀ er-
ent pathways, especially in diﬀ erent cell types [466]. It 
has been hypothesized that the speciﬁ c signaling path-
ways activated by RAGE ligands are greatly dependent 
on the duration of ligand stimulation and the speciﬁ c 
functions of each cell type [455]. For example, RAGE 
ligands result in increased serine 9 phosphorylation of 
GSK-3 β in smooth muscle cells, a process which causes 
increased smooth muscle cell migration [467]. On the 
other hand, in primary murine adult cardiomyocytes, 
RAGE ligands mediate decreased phosphorylation of ser-
ine 9 GSK-3 β , which is linked to increased activation of 
cell death pathways in these cells [468]. These data sug-
gest that the actions of RAGE ligands are highly depen-
dent on the type, properties, stress responses, and fate of 
the impacted cells. 
 RAGE activation is known to be involved in the patho-
genetic mechanism of some oxidative-based diseases 
including diabetes, atherosclerosis, AD, and chronic air-
way diseases. Based on these premises, the AGE – RAGE 
damaging axis is now considered as a promising drug tar-
get and hence the compounds acting by inhibiting the 
RAGE-mediated signal have been found able to exert a 
beneﬁ cial eﬀ ect in various pathologies. The main molecu-
lar approaches used to inhibit the RAGE activation can be 
grouped into the following classes: (i) inactivating ligands 
or using RAGE-truncated and soluble forms able to bind 
the circulating RAGE agonists; (ii) inactivating RAGE, 
for example, through antibodies or by use of RAGE 
antagonists, blocking the AGE/RAGE damaging axis; 
(iii) downregulating RAGE expression, and (iv) inhibiting 
the signal transduction pathway that follows ligand – RAGE 
interaction. 
 Inactivating ligand 
 Apart from full-length RAGE present in the plasma mem-
brane (fRAGE), there exist a population of shortened 
RAGE (sRAGE) circulating in blood and body ﬂ uids, 
which lack the transmembrane domain. sRAGE comprises 
a heterogeneous population that includes an endogenous 
secretory isoform generated via alternative splicing 
(endogenous secretory receptor for AGEs, esRAGE) and 
a form generated through proteolytic cleavage of the full-
length cell surface receptor by the action of membrane-
associated matrix MMPs such as a disintegrin and MMP10 
and MMP9 (Figure 9). The sRAGE may be subject to 
further proteolytic cleavage, generating miniRAGE com-
prising only the V and C1 domains; miniRAGE is not 
subjected to further degradation and is still able to bind 
ligands due to the presence of the V domain. It has an 
even higher sensitivity to AGEs compared with that of the 
full-length sRAGE [469]. Circulating sRAGEs are detect-
able in human plasma and are able to bind ligands, com-
peting with membrane-bound RAGE. However, sRAGEs 
lack the intracellular signaling domain, and therefore, its 
engagement with ligands does not trigger signal transduc-
tion so, competing for the ligands of RAGE, it can have 
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levels of sRAGE in patients with acute Kawasaki disease 
were found, suggesting the potential anti-inﬂ ammatory 
eﬀ ect of sRAGE in inﬂ ammatory vascular disorders [478]. 
The level of circulating sRAGE decreases in rats after 
middle cerebral artery occlusion and may be a peripheral 
biomarker of focal ischemia [479]. sRAGE may reﬂ ect 
some peripheral plasma features of the pathophysiological 
process of AD. Decreased plasma levels of sRAGE in 
patients with AD have been documented. Comparison of 
the plasma levels of sRAGE in patients with AD, vascular 
dementia (VaD), non-AD neurodegenerative dementias 
(NND), and cognitively normal controls (NC) showed a 
signiﬁ cantly lower concentration of plasma sRAGE in the 
group with AD compared with those in the VaD or NC 
group [480]. These examples demonstrate that the level of 
sRAGE may be a useful biomarker of diseases. 
 sRAGE has indeed potent anti-inﬂ ammatory properties 
by acting as a decoy for RAGE ligands. sRAGE binds with 
high aﬃ  nity to atherogenic low-density lipoprotein (LDL) 
modiﬁ ed by hypochlorous acid (HOCl), the major oxidant 
generated by the myeloperoxidase-H 2 O 2 -chloride system 
of phagocytes activated during inﬂ ammation, acting as a 
sink for HOCl-LDL, which is abundantly present in human 
atherosclerotic lesions. sRAGE can be coprecipitated with 
HOCl-LDL from spiked serum. It has been proposed that 
sRAGE represents a physiological antagonist that inter-
feres with scavenger receptor-mediated cholesterol accu-
mulation and foam cell formation of macrophages [481]. 
A signiﬁ cant inverse correlation between circulating lev-
els of sRAGE and oxLDL has, indeed, been found, which 
suggests that part of the anti-atherosclerotic eﬀ ects of 
sRAGE may be related to oxLDL quenching [482]. 
 The endogenous phospholipid lysophosphatidic acid 
(LPA) regulates fundamental cellular processes such as 
proliferation, survival, motility, and invasion implicated 
in homeostatic and pathological conditions.  In vitro , 
RAGE was found to be required for LPA-mediated signal 
transduction in vascular smooth muscle cells and C6 
glioma cells, proliferation, and migration.  In vivo , the 
administration of soluble RAGE mitigated LPA-stimulated 
vascular Akt signaling, autotaxin/LPA-driven phosphory-
lation of Akt and cyclin D1 in the mammary tissue of 
cytoprotective eﬀ ects [470,471]. The balance between the 
levels of RAGE ligands, cell surface RAGE, and sRAGE/
esRAGE represents, thus represent a complex dynamic 
system, which state is inﬂ uenced by diseases and drugs, 
and which may be of diagnostic importance. 
 In liver pathology, the expression of RAGE and its 
ligands (AGEs, CML, and HMGB1) increases, whereas 
the expression of sRAGE decreases. A negative feedback 
has been shown to exist for sRAGE when RAGE interacts 
with its ligands [470]. Higher circulating levels of sRAGE 
are associated with reduced risks of coronary artery dis-
ease, hypertension, metabolic syndrome, and other chronic 
diseases. In a colonoscopy-based case – control study, the 
associations between plasma levels of sRAGE, sTNF- α RI, 
sTNF- α RII, sIL-6R, EGF, IFN α 2, G-CSF, MCP1, TNF β , 
and VEGF with the risk of colorectal adenoma were 
estimated. An inverse association between sRAGE and 
colorectal adenoma was found among those without 
hypertension [471]. In Italian male subjects without dia-
betes, lower levels of plasma esRAGE were associated 
with enhanced risk of angiographically detected coronary 
artery disease [472]. In type 1 diabetic patients, circulating 
esRAGE levels were signiﬁ cantly lower than in non-
diabetic subjects and were inversely associated with the 
severity of some diabetic vascular complications [473]. 
Low circulating esRAGE levels were found to be predic-
tive for cardiovascular mortality in both non-diabetic and 
diabetic patients with end-stage renal diseases [473,474]. 
It should be noted, however, that another authors found 
higher serum sRAGE levels in type 2 diabetic patients 
than in non-diabetic subjects, positively associated with 
the presence of coronary artery disease [475]. 
 18 F-Fluorodeoxyglucose positron emission tomography 
(FDG-PET) is a novel imaging technique for detecting 
vascular inﬂ ammation. Vascular  18 F-FDG uptake was 
measured as the blood-normalized standardized uptake 
value (SUV), known as the target-to-background ratio 
(TBR). Circulating sRAGE showed a signiﬁ cant associa-
tion with TBR values measured using FDG-PET, which 
reﬂ ect vascular inﬂ ammation [476]. A recent study sug-
gested that sRAGE may be one of the biomarkers diagnos-
ing post-stroke cognitive impairment [477]. Decreased 
 Figure 9. The structure of full-length RAGE and its variants. The V-type domain is critical for binding of RAGE – ligand axis. Deletion of 
this domain results in an N-truncated form that does not bind ligands. The C-truncated, circulating soluble RAGE contains only the 
extracellular domain of the receptor. It may be a result of alternate endogenous splicing (esRAGE) or proteolytic cleavage. 
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transgenic mice vulnerable to carcinogenesis, and ovarian 
tumor implantation and development. A novel role for 
RAGE as a conduit for LPA signaling has been identiﬁ ed 
and targeting LPA-RAGE interaction has been suggested 
as a therapeutic strategy to modify the pathological 
actions of LPA [483]. 
 The protective role of sRAGE prompted interest in stud-
ies on how various drugs aﬀ ect the level of circulating 
sRAGE. Interestingly, traditional cardiovascular drugs 
(statins, thiazolidinediones, angiotensin-converting enzyme 
(ACE) inhibitors, and angiotension AT-1 receptor antago-
nists) as well as nutraceuticals (grape seed proanthocyani-
din extract) can modulate RAGE expression and circulating 
sRAGE levels in cardiovascular disease states character-
ized by enhanced RAGE activation, which may represent 
a novel mechanism of their action [484]. 
 Introduction of recombinant sRAGE may be expected 
to become a new way of therapy to prevent the activation 
of RAGE by proinﬂ ammatory ligands. In experiments on 
acetaminophen-induced liver injury, animals treated with 
sRAGE displayed increased survival compared with vehi-
cle treatment, and markedly decreased hepatic necrosis. 
Consistent with an important role for RAGE-triggered 
oxidant stress in hepatic injury, a signiﬁ cant reduction of 
protein nitrotyrosine was observed in hepatic tissue in 
sRAGE-treated versus vehicle-treated mice receiving 
acetaminophen, in parallel with signiﬁ cantly increased 
level of GSH. In addition, pro-regenerative cytokines 
tumor necrosis factor-alpha and interleukin-6 were 
increased in sRAGE-treated versus vehicle-treated mice 
[485]. RAGE blockade by genetically engineered sRAGE 
was found to reduce vascular complications in a diabetic 
animal model [486,487]. 
 Inactivating RAGE 
 Another therapeutical approach consists in inactivating 
RAGE. The receptor can be inactivated by high-
molecular-weight substrate analogs, low-molecular-weight 
inhibitors, or anti-RAGE antibodies, neutralizing the 
receptor. A set of compounds have been proposed as 
RAGE inhibitors and tested in animal models. 
 Low-molecular-weight antagonists of RAGE 
 Probably due to the complexity of the molecular interac-
tions between AGEs-RAGE, only few studies on AGE 
antagonists have so far been reported. Most of the studies 
on the rational design of RAGE antagonists have been 
carried out by considering amyloid  β -peptide (A β ) as a 
ligand [488]. Also in this case, the molecular interaction 
between A β and RAGE is not completely elucidated: by 
using ﬂ uorescence and MS, it has been found that the 
major V-RAGE binding region of A β involves a highly 
hydrophobic stretch,  17 LVFFAED 21 and a ﬂ anked nega-
tively charged residue D 22 E 23 at the C terminus. The inter-
est of A β as RAGE ligand is due to the fact that the 
A β -RAGE axis is involved in the AD and represents an 
emerging drug target. In particular, in brain endothelium, 
RAGE mediates the inﬂ ux of circulating A β into the brain 
while in neurons, it mediates A β -induced oxidant stress 
and A β intraneuronal transport, causing mitochondrial 
dysfunction. A β – RAGE interaction also activates nuclear 
factor- κ B (NF- κ B), which plays a crucial role in various 
inﬂ ammatory responses. 
 Zlokovic et  al. reported the structure of RAGE antag-
onist with a K d in a nanomolar range. The lead com-
pounds from the ﬁ rst screening shared common structural 
moieties such as a tertiary amide moiety substituted with 
a hydrophobic moiety and a monosubstituted aromatic 
group. A second-generation library of compounds was 
then synthesized on the basis of the chemical features 
retrieved from the ﬁ rst library. From the second library, 
a compound coded as FPS-ZM1 was identiﬁ ed and 
characterized by a favorable inhibitory and dissociation 
constants (K i /K d    0.66) as well as suitable pK and bio-
availability properties. Structure – activity relationship 
studies revealed that the tertiary amide and aromatic 
rings are essential for activity and that the chlorine atom 
on the electron poor aromatic group may enhance its 
binding to the receptor [489]. Besides  in vitro studies, 
FPS-ZM1 was also found eﬀ ective in a mouse model of 
AD inhibiting the RAGE-mediated inﬂ ux of circulating 
A β 40 and A β 42 into the brain,  β -secretase activity, A β 
production and microglia activation and neuroinﬂ amma-
tion, and normalizing cognitive performance and cerebral 
blood ﬂ ow responses [488]. 
 PF-04494700 (previously known as TTP488), an orally 
bioavailable low-molecular-weight inhibitor of RAGE, 
which inhibits sRAGE from binding to RAGE ligands, 
S100B, amphoterin, and CML has been developed as a 
potential treatment for AD (as well as diabetic nephropa-
thy) and has reached a phase II clinical trial [490] but was 
discontinued in 2011 due to a poor eﬃ  cacy. Feng et  al. 
demonstrated that CM-1, a cell protecting agent able to 
prevent AGE-induced endothelial dysfunction, blocks the 
interaction of MGH-1 with RAGE by acting as a com-
petitive high-aﬃ  nity antagonist, with IC 50  values in the 
nanomolar range [491]. A screen of 50 compounds for 
their ability to prevent binding to RAGE of a ﬂ uorescent 
AGE-BSA derivative in RAGE-overexpressing cells 
demonstrated that genistein inhibits this binding in a 
dose-dependent manner at nM concentrations [492]. Thi-
azolidinediones, calcium channel blockers, angiotensin-
converting enzyme inhibitors, angiotensin II receptor 
blockers, and statins are reported to suppress RAGE 
expression [493]. 
 There is no essential diﬀ erence in the binding with 
RAGE between the macromolecular and monomeric 
AGE. Monomeric AGEs, which generally consist of an 
N-heterocyclic moiety and an amino acid moiety as a part 
of the AGE   protein linkage are thus attractive as a tem-
plate for the design of novel small-molecule RAGE antag-
onists. In particular, argpyrimidine 1, a monomeric AGE, 
was selected for design of the incipient RAGE antagonists, 
because the key structure of argpyrimidine seems to 
provide more synthetic accessibility and more drug-like 
features compared with that of other monomeric AGEs. 
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Using the approach of ligand-based drug design, the group 
of Suh discovered a novel series of 4,6-disubstituted 
2-aminopyrimidines as RAGE antagonists. In transgenic 
mouse models of AD, one of the 4,6-bis(4-chlorophenyl)
pyrimidine analogs (59) signiﬁ cantly lowered the concen-
tration of toxic soluble A β in the brain and improved 
cognitive function. 59 binds directly to RAGE and thus 
inhibits the RAGE – A β interaction. A docking study pre-
dicted also the binding mode of the 4,6-bis(4-chlorophe-
nyl)pyrimidine analogs to the RAGE V-domain [459]. 
 Peptides and polysaccharides 
 A study of interaction of a series of truncated versions of 
A β with RAGE demonstrated that such peptides may also 
be RAGE antagonists, preventing binding of true A β 
[494]. It has not yet been demonstrated whether a RAGE 
antagonist designed and tested by considering A β as 
ligand is also eﬀ ective as inhibitor of the AGE – RAGE 
interaction; however, literature data suggest that it may be 
the case. 
 Hearst et  al. reported that the newly designed S100B 
inhibitory peptide, Synb1-ELP-TRTK, has a capacity to 
block the RAGE-mediated uptake of S100B in neuroblas-
toma cells, what makes it a promising agent against cer-
ebellar neurodegenerative disorders [495]. Systemic 
administration of another RAGE antagonist, a S100P-
derived peptide, reduced the growth and the metastasis of 
pancreatic tumors and also inhibited glioma tumor growth 
in animal models [496]. 
 Heparin and its derivatives, 2- O ,3- O -desulfated hepa-
rin (ODSH), also block ligation of RAGE with a number 
of its important ligands, including the AGE-product CML-
bovine serum albumin, HMGB-1, and S100 calgranulins. 
Heparin inhibits many proteins through electrostatic 
charge interactions with cationic amino acids. Electro-
static charge interactions may also play an important role 
in ligand – RAGE binding. Heparin and non-anticoagulant 
heparins such as ODSH might be expected to disrupt these 
interactions by competing with AGEs for binding to the 
cationic V region. Because heparin and ODSH are large, 
long polymers, their electrostatic attachment to the V 
domain of RAGE might also cause steric hindrance for 
S100/calgranulin binding to adjacent C1 and C2 domains. 
Low-molecular-weight heparin (LMWH) also can bind to 
RAGE and act as an antagonist to RAGE. LMWH treat-
ment of mice showed preventive and therapeutic eﬀ ects 
on albuminuria and increased glomerular cell number, 
mesangial expansion, and advanced glomerulosclerosis in 
a dose-dependent manner [497]. 
 Antibodies 
 The most common approach to the prevention of deleteri-
ous outcomes of RAGE activation in  in vitro system and 
animal models is the application of inactivating monoclo-
nal or polyclonal antibodies against RAGE. Such antibod-
ies were found to prevent the NADPH oxidase activation 
induced by RAGE ligand binding, subsequent oxidative 
stress in the cells (generation of reactive oxygen and nitro-
gen species, increase in MDA and protein carbonyl con-
tent) [498] and various indirect sequelae of this activation. 
For example, application of anti-RAGE antibodies attenu-
ated AGE-induced increased expression of K Ca3.1 channels 
in cardiac ﬁ broblasts [499], activation of the renin-
angiotensin system through the RAGE/phosphoinositide 
3-kinase signaling pathway [500], pulmonary metastasis 
of tumor cells [501], delayed-type hypersensitivity reac-
tions, collagen-induced arthritis, experimental autoim-
mune encephalomyelitis, and alloimmunity [502]. 
 Pretreatment with endogenous anti-RAGE antibodies 
isolated from transgenic APPSWE-PS1 mice expressing 
human presenilin 1 (A246E variant) and a chimeric amy-
loid precursor protein prevented A β 1-42-induced neuro-
toxicity in cultured primary rat cortical neurons [503]. 
HMGB1, like AGE, reduces collagen synthesis by ﬁ bro-
blasts; this eﬀ ect was abrogated by co-treatment with an 
anti-RAGE antibody [504]. 
 One of the antibodies against RAGE, designated 
XT-M4, a rat-derived anti-mouse RAGE monoclonal anti-
body, binds the extracellular region of RAGE and inhibits 
the interaction of RAGE with multiple ligands. XT-M4 
has a broad species cross-reactivity, a binding aﬃ  nity of 
0.3 nM for murine dimeric RAGE and was protective in 
the mouse cecal ligation and puncture-induced (CLP) 
model of sepsis. The humanized XT-M4 antibody main-
tains all the inhibitory and binding properties of the paren-
tal rat XT-M4 antibody and also showed eﬃ  cacy in the 
mouse model of pneumococcal pneumonia [505]. Admin-
istration of humanized anti-RAGE monoclonal antibody 
after intratracheal infection with  Streptococcus pneumo-
niae decreased mortality in mice and modulated expres-
sion of genes, especially those involved in the inﬂ ammatory 
response [506].  In vitro , anti-RAGE antibody protected 
podocytes against AGE-induced dysfunction [507]. 
 Downregulation of RAGE expression 
 There is a considerable interest in the possibility of down-
regulation of RAGE expression by drugs and natural sub-
stances. For some drugs, this mechanism, interestingly, 
may represent a secondary mechanism of their action. 
 Peroxisome proliferator-activated receptor gamma 
(PPAR- γ ), a nuclear receptor, is highly expressed in all 
cells involved in vascular pathologies, including mac-
rophages, endothelial cells, and smooth muscle cells [508]. 
PPAR- γ synthetic ligands such as pioglitazone and rosigl-
itazone improve insulin resistance in diabetic patients, and 
now become one of the most popular anti-diabetic drugs 
in the developed countries [509]. Accumulating data indi-
cate that PPAR- γ agonists can downregulate the expres-
sion of RAGE both  in vitro and  in vivo [508]. This eﬀ ect 
has been demonstrated for several of the thiazolidinedione 
class of insulin-sensitizing PPAR- γ agonists including 
pioglitazone [510,511] and rosiglitazone [512]. RAGE 
activation-induced inﬂ ammation promotes aortic valve 
calciﬁ cation in hypercholesterolemic rabbits, which can 
be attenuated by pioglitazone treatment [508]. Nifedipine, 
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a calcium-channel blocker, also suppresses RAGE expres-
sion through PPAR- γ activation [513]. 
 An anti-diabetic drug commonly used in the treatment 
of Type II diabetes, metformin, downregulates RAGE 
expression, which may be another facet of its action [514]. 
Metformin inhibits the AGEs-induced growth and VEGF 
expression in MCF-7 breast cancer cells by suppressing 
RAGE gene expression via AMP-activated protein kinase 
pathway. Due to this eﬀ ect, metformin may protect against 
breast cancer expansion in diabetic patients by blocking 
the AGE – RAGE axis [514]. Irbesartan, an angiotensin II 
type 1 receptor antagonist used mainly for the treatment 
of hypertension, was also found to downregulate RAGE 
expression [515]. The combination therapy with met-
formin and irbesartan may have therapeutic potential in 
diabetic nephropathy. It can play a protective role against 
tubular injury in diabetes not only by inhibiting AGEs 
formation, but also by attenuating the deleterious eﬀ ects 
of AGEs via downregulating RAGE expression [516]. 
Downregulation of RAGE expression was observed for 
other angiotensin II type 1 receptor blockers, telmisartan 
[517], and olmesartan [518], too, and ascribed mainly to 
the activation of PPAR- γ [517]. 
 Vardenaﬁ l, an inhibitor of phosphodiesterase 5, can 
block the AGE-induced upregulation of monocyte chemoat-
tractant protein-1 (MCP-1) mRNA levels in human umbil-
ical vein endothelial cells (HUVECs) by suppressing 
RAGE expression via the elevation of cGMP [519]. RAGE 
downregulation was also noted for glucagon-like peptide-1 
[520] and pigment epithelium-derived factor [521]. 
Another class of drugs used to lower cholesterol levels, 
statins (e.g., pravastatin), known to ameliorate renal func-
tion and reduce proteinuria in patients with chronic kidney 
disease, decreases RAGE expression [522]. It was also 
demonstrated that pentoxifylline (PTX), a non-selective 
phosphodiesterase inhibitor, may show protective eﬀ ects 
on hepatic and arterial functions, partially through the 
inhibition of RAGE expression [523]. 
 As mentioned above, many natural compounds can 
also downregulate RAGE expression. RAGE downregu-
lation was reported, that is, for resveratrol [524] and for 
various plant extracts, of complex composition. Curcumin 
downregulated RAGE expression in rats with experimen-
tal diabetes [525]. Paeoniﬂ orin, isolated from the root of 
 Paeonia , reported to exert an anti-inﬂ ammatory eﬀ ect, 
downregulates RAGE expression in HUVECs [526]. 
Puerarin, a major isoﬂ avonoid derived from the Chinese 
medical herb  Radix puerariae (kudzu root), decreases or 
inhibits RAGE expression in retinas of STZ-induced early 
diabetic rats [527]. Pinocembrin, a ﬂ avonoid abundant in 
propolis, inhibits upregulation of RAGE in an animal 
model of AD [528]. Ursolic acid, a pentacyclic triterpene 
acid present in many plants, including apples (especially 
apple peels), basil, bilberries, cranberries, elder ﬂ ower, 
peppermint, rosemary, lavender, oregano, thyme, haw-
thorn, and prunes, also downregulates RAGE expression 
[529]. Administration of extract of  Salvia miltiorrhiza to 
early diabetic rats decreased the expression of RAGE in 
the kidneys [530]. In a similar model, increased RAGE 
expression in the aorta was attenuated by a  Hibiscus 
sabdariﬀ a polyphenolic extract [531]. Xu et  al. [532] 
evaluated the potential pathological role of RAGE and 
nuclear factor-kappa BP65 in diabetic encephalopathy. 
The results obtained by these authors indicated that grape 
seed proanthocyanidin extracts decrease the expression of 
RAGE and suggest that grape seed proanthocyanidin 
extracts might be a useful remedy in the treatment of 
diabetic encephalopathy [532]. RAGE downregulation 
was also demonstrated for extract from the Japanese 
apricot, MK615 [533], methanol extract of  Lycium 
barbarum (Goji Berry) as well as its main component, 
taurine [534]. Extract of  Ginkgo biloba , a traditional 
Chinese medicine (EGb761), found to protect brain from 
hypoxic damage and ROS generation and considered as a 
therapeutic agent against AD, was demonstrated to down-
regulate RAGE expression in immortalized mouse endothe-
lial cells [525,535]. Aqueous extract of  Rehmannia 
glutinosa , a plant traditionally prescribed in Korean medi-
cine to reduce fever and regulate immunity, suppresses 
inﬂ ammation and RAGE expression [536]. Recently, 
retinol was documented to decrease RAGE levels, suggest-
ing that RAGE downregulation may exert a role in the 
deleterious eﬀ ects observed in some retinol supplementa-
tion therapies, especially in the lungs [537]. Selenium 
supplementation downregulated the expressions of both 
NFkB and RAGE is rats with STS-induced diabetes [538]. 
Oral administration of ﬁ sh oil with high levels of (n-3 
PUFAs) following small bowel transplantation signiﬁ cantly 
reduced the HMGB1 and RAGE expression, which coin-
cided with the amelioration of chronic allograft vasculopa-
thy. In contrast, feeding of corn oil that contained low 
levels of n-3 PUFAs had no favorable eﬀ ects on chronic 
allograft vasculopathy development and failed to decrease 
the HMGB1 and RAGE expression [539]. 
 The development of nanomedicine brings new possi-
bilities of modulation of RAGE expression. It was reported 
that combination of 3- to 5-nm gold nanoparticles, epigal-
locatechin gallate, and  α -lipoic acid prevents upregulation 
of RAGE expression in diabetic wound [540]. 
 Inhibiting the signal transduction pathway that follows 
ligand-RAGE interaction 
 Reports from multiple laboratories indicate that ligand –
 RAGE interaction stimulates signal transduction and 
that such signaling is essential for RAGE-dependent 
modulation of gene expression and fundamental cellular 
properties [455]. RAGE activation results in the activation 
of Ras-extracellular signal-regulated kinase 1/2 (ERK1/2), 
p21ras, Cdc42/Rac, stress-activated protein kinase/c-Jun-
NH2-terminal kinase (SAPK/JNK) and p38 MAP kinases 
(p38 MAPK), phosphoinositol-3 kinase and rhoGTPases, 
eventually impinging on canonical NF- κ B, AP-1, CREB, 
STAT3, NFAT signaling pathways, and myogenin with 
consequent changes in the transcription of an array of 
genes coding for cytokines, inﬂ ammatory enzymes, 
chemokines, chemokine receptors, adhesion molecules, 
matrix MMPs, and/or cytoskeletal constituents which 
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aﬀ ect cell proliferation, survival, diﬀ erentiation 
and migration, phagocytosis and authophagy [458,541] 
(Figure 10). 
 NF- κ B-DNA binding is associated with the expression 
of an altered cellular phenotype including the expression 
of adhesion molecules for circulating inﬂ ammatory cells 
such as VCAM-1 and ICAM-1, monocyte chemoattractant 
protein-1 (MCP-1), plasminogen activator inhibitor-1 
(PAI-1), tissue factor, vascular endothelial growth factor, 
endothelin-1, E-selectin, thrombomodulin, and proinﬂ am-
matory cytokines, including interleukin (IL)-1 α , IL-6, 
tumor necrosis factor- α and RAGE itself [541 – 543]. These 
cytokines and adhesion molecules promote an inﬂ amma-
tory response with associated cellular migration and pro-
liferation and play have central roles in both inﬂ ammation 
and atherosclerosis [544]. What is important, ligation of 
RAGE causes a positive feed-forward loop, in which 
inﬂ ammatory stimuli activate NF- k B, which in turn 
induces RAGE expression, followed again by NF- k B 
activation [493,545]. 
 The cytoplasmic domain of RAGE is phosphorylated 
at Ser391 by PKC ζ upon binding of ligands. TIRAP and 
MyD88, which are known to be adaptor proteins for Toll-
like receptor-2 and Toll-like receptor-4 (TLR2/4), bound 
to the phosphorylated RAGE and transduced a signal to 
downstream molecules. Blocking of the function of TIRAP 
and MyD88 largely abrogated intracellular signaling from 
ligand-activated RAGE. These ﬁ ndings indicate that func-
tional interaction between RAGE and TLRs coordinately 
regulates inﬂ ammation, immune response, and other cel-
lular functions [546]. 
 AGE – RAGE-mediated ROS generation activates TGF-
beta – Smad signaling and subsequently induces mesangial 
cell hypertrophy and ﬁ bronectin synthesis by autocrine 
production of angiotensin II. This pathway may provide 
an important link between the AGE – RAGE axis and the 
RAS in promoting the development and progression of 
CKD [547]. 
 Recently, mDia1 (a mammalian homologue of 
 Drosophila gene  Diaphanous 1 ) has been identiﬁ ed as a 
direct binding partner of an intracellular domain of RAGE 
and as a part of the machinery of RAGE intracellular sig-
naling. RAGE binds the FH1 domain of mDia1 at least in 
part through the interaction of R5/Q6 amino acids of the 
human RAGE cytoplasmic tail (ctRAGE) [455,483]. 
ctRAGE contains an unusual  α -turn that mediates the 
mDia1 – ctRAGE interaction and is required for RAGE-
dependent signaling. mDia1 is required for AGE-mediated 
upregulation of Egr-1 in macrophages exposed to hypoxia 
[548]; it is required for RAGE ligand (AGE and S100B)-
stimulated migration; activation of Rac-1 and Cdc42 in 
transformed cells [549]; S100B-mediated activation of 
Rac1, Akt and GSK-3 β ; generation of oxidative stress; and 
cellular migration in primary murine aortic smooth mus-
cle cells [467]. Experiments are underway to probe the 
impact of mDia1 in murine models of diabetic complica-
tions. If these studies identify that mDia1 is essential for 
macro- and microvascular complications, such data may 
highlight novel areas for therapeutic intervention in dia-
betes. In addition, diaphanous 1 recruits Rac1 and Cdc42 
in glioma cells, thereby driving RAGE-dependent cell 
migration. Also, following RAGE ligation by S100B in 
microglia, mDia1 recruits Rac1/Cdc42 with ensuing acti-
vation of a RhoA/ROCK and a Src kinase/Ras/PI3K/
RhoA/ROCK pathway governing microglial motility and 
a JNK/AP-1 pathway responsible for chemokine expres-
sion [458]. 
 Extensive literature analysis identiﬁ ed 95 molecules 
involved in the AGE/RAGE axis signaling. The map of 
these interactions is available freely in NetSlim at http://
www.netpath.org/netslim/age_signaling_pathways.
html [550]. 
 One of the best documented consequences of RAGE 
activation is the generation of ROS. ROS are produced by 
upregulation of subunits of NADPH oxidase, including 
p47phox (11), nox-4 (12), and p22phox, and activation of 
this superoxide-producing enzyme [551,552]. AGEs 
increase the expression of both the mRNA and protein 
levels of NADPH oxidase p47phox that are in turn blocked 
by anti-RAGE antibodies, conﬁ rming that NADPH oxi-
dase is a downstream target of RAGE in AGE-induced 
ROS pathway in SH-SY5Y cells and rat cortical neurons. 
AGE-induced oxidative stress contributes to ER stress, 
and the cell death induced by ER stress is involved by C/
EBP homologous protein (CHOP) and caspase-12. Inhib-
iting both AGE – RAGE – NADPH-ROS scavenging path-
ways and ER stress can lead to the prevention of cell death. 
The signaling pathway involved during AGE-induced 
apoptosis identiﬁ ed in the current study suggested that 
targeting RAGE, NADPH oxidase, ROS scavenging, or 
ER stress may also be a potential novel approach for the 
prevention of RAGE-induced neurodegeneration [553]. 
 The primary ROS generated by NADPH oxidase is 
superoxide but it dismutates to hydrogen peroxide in a 
reaction catalyzed by SOD or occurring spontaneously 
(albeit at a much lower rate). Superoxide may react with 
nitric oxide to form peroxynitrite while hydrogen peroxide 
may produce hypochloric acid/hypochlorite in a reaction 
catalyzed by myeloperoxidase. Thus, RAGE activation 
produces a set of ROS damaging constituents of cells and 
of extracellular matrix. Although produced mainly for the 
sake of signaling, these ROS contribute signiﬁ cantly to  Figure 10. Intracellular eﬀ ects of AGEs mediated by RAGE. 
Fr
ee
 R
ad
ic
 R
es
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ita
 S
ta
ta
le
 M
ila
no
 o
n 
01
/2
7/
14
Fo
r p
er
so
na
l u
se
 o
nl
y.
  Preventing glycoxidation and lipoxidation  121
oxidative stress occurring in diabetes and other diseases. 
Sustained NADPH oxidase activation compromises sev-
eral anti-oxidant systems by depleting NADPH [554]. 
 Blockade of the RAGE downstream signaling may be 
a promising target for therapeutic intervention in diabetic 
vascular complication, apart from downregulation of 
RAGE expression. Various attempts in this direction have 
been made. In many cases, it is hard to decide whether the 
observed eﬀ ect is due to downregulation of RAGE expres-
sion, inhibition of downstream signaling, or both. One 
obvious target intervention is the ROS production which 
may be aﬀ ected by NADPH oxidase inhibitors; otherwise, 
antioxidants may attenuate the RAGE-initiated signaling 
by reacting with ROS. However, ROS generation occurs 
also at the earlier stage of glycoxidation so the interpreta-
tion of the eﬀ ect of antioxidants is not simple. RAGE 
overexpression was found to inhibit osteoblast prolifera-
tion  in vitro via suppression of Wnt, PI3K, and ERK 
signaling. Prevention of Wnt signaling using Sfrp1 or 
DKK1 rescues RAGE-decreased PI3K and ERK signaling 
and cell proliferation [508]. 
 AGEs induce proliferation of vascular smooth muscle 
cells, which involves autophagy. Treatment with AGEs 
activates ERK, JNK, and p38/MAPK, but inhibits Akt. 
Pretreatment with an ERK inhibitor and an Akt activator 
inhibits AGE-induced autophagy [555]. Similarly, exces-
sive production of matrix MMP IX by HaCaT keratino-
cytes dependent on RAGE activation is attenuated by 
inhibitors of downstream elements of the RAGE signaling 
pathway: ERK1/2 (U0126), p38 mitogen-activated protein 
kinase (SB203580), and NF- κ B [556]. 
 Treatment of neutrophils with AGEs increases genera-
tion of superoxide and nitric oxide by NADPH oxidase 
and iNOS, respectively, which is inhibited by diphenyle-
neiodonium, an inhibitor of both enzymes, hexameth-
ylphosphoric triamide (HMPA), inhibitor of NADPH 
oxidase, or anti-RAGE antibodies [542,557], although 
other classes of NOS, especially eNOS, are rather attenu-
ated than activated by RAGE activation. The inhibitor of 
NADPH oxidase, apocynin, improves renal function in 
STZ-induced diabetic rats, albeit over a relatively short 
period [558]. SOD and antioxidants such as probucol, 
 a -tocopherol,  a -lipoic acid, and N-acetyl-cysteine (NAC) 
provide cytoprotection against AGEs [559,560]; the eﬀ ects 
of the burst of ROS production are enhanced by GSH 
depletion [545]. Activation of RAGE by AGE induces 
oxidative stress in endothelial and other cells, including 
the generation of thiobarbituric acid-reactive substances 
(TBARS), activation of NF-kappa B, and induction of 
heme oxygenase I; these eﬀ ects are blocked by antibodies 
to RAGE and by antioxidants [559]. Nifedipine, a calci-
um-channel blocker, inhibits the AGE-induced RAGE 
upregulation [513]; this eﬀ ect was ascribed to inhibition 
of ROS generation [561]. Irbesartan, an angiotensin II 
type 1 receptor blocker, also downregulates RAGE expres-
sion and attenuates ROS formation in kidney tubular cells 
[515]. Similarly, olmesartan was found to decrease AGE-
evoked ROS generation in endothelial cells [562]. Piogli-
tazone inhibits NF- κ B activation as well [508,563]. Statins 
have a similar eﬀ ect as demonstrated for pravastatin in 
proximal tubular epithelial cells from human kidney [522]. 
From among natural compounds, quercetin was found to 
downregulate RAGE expression and inhibit the RAGE-
initiated ERK/CREB/BDNF signaling pathway [564]. 
Rosiglitazone and pioglitazone diminish the RAGE pro-
tein expression in human endothelial cells, decreasing 
AGE-BSA and beta-amyloid-induced MCP-1 production. 
A recent study highlights the detrimental role of RAGE 
activation and RAGE signaling in the development 
and progression of aortic valve (AV) calciﬁ cation [508]. 
Pretreatment with Bay 11 – 7082, an NF- κ B inhibitor, 
inhibited RAGE-mediated upregulation of Runx2 and 
osteopontin. These results indicate that NF- κ B activation 
mediates AGE-BSA-induced proinﬂ ammatory eﬀ ects and 
osteoblastic diﬀ erentiation of cultured porcine aortic valve 
interstitial cells (VICs). 
 Curcumin alleviates diabetic cardiomyopathy in a rat 
model decreasing RAGE expression markers of oxidative 
stress, Rac1 activity, NADPH oxidase subunits expres-
sion of gp91(phox) and p47(phox), inﬂ ammatory factors 
(TNF- α and IL-1 β ) and inhibiting Akt and GSK-3 β phos-
phorylation [525]. Similar eﬀ ects were noted for soybean 
isoﬂ avones [565]. Pinocembrin signiﬁ cantly inhibits the 
upregulation of RAGE transcripts and protein expression 
both  in vivo and  in vitro , and also markedly depresses 
the activation of p38 mitogen-activated protein kinase 
(MAPK)-MAPKAP kinase-2 (MK2)-heat shock protein 
27 (HSP27) and stress-activated protein kinase (SAPK)/
c-Jun N-terminal kinase (JNK)-c-Jun pathways and the 
downstream NF κ B inﬂ ammatory response subsequent 
to A β -RAGE interaction. Pinocembrin was shown to 
infer cognitive improvement and neuronal protection in 
Alzheimer disease models [528]. Kaempferol abrogates 
age-related upregulation of the RAGE axis by inhibition 
of NADPH oxidase and preventing activation of 
NFkappaB [554]. Taurine blocks the AGE-induced Raf-1/
extracellular signal-regulated kinase (ERK) activation in 
epithelial cells and the subsequent cell hypertrophy [566]. 
Quercetin treatment for A β (25 – 35)-induced amnesic mice 
improved the learning and memory capabilities and con-
ferred robust neurovascular coupling protection, invol-
ving maintenance of the NVU integrity, reduction of 
neurovascular oxidation, modulation of microvascular 
function, improvement of cholinergic system, and down-
regulation of neurovascular RAGE signaling pathway 
and ERK/CREB/BDNF pathway [567]. Ursolic acid 
attenuates D-gal-induced inﬂ ammatory response in the 
prefrontal cortex of D-gal-treated mice through decreasing 
AGEs, ROS, and protein carbonyl levels and inhibits AGE/
RAGE/NF- κ B-mediated inﬂ ammatory response [568]. 
 Final remarks 
 Formation of AGEs and ALEs is a feature of parametabo-
lism, that is, metabolic reactions which are not pro-
grammed and teleonomic but occur due to the chemical 
properties of metabolites [569]. Although they may be 
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involved in cellular signaling [570,571], their excess con-
tributes to the development of diabetic complications and 
other pathologies. The complexity of formation and inter-
actions of AGEs and ALEs makes it possible to interact 
with these processes at various levels. The compounds 
discussed in this review and new, which are to be discov-
ered, can be invaluable in combating diseases aﬀ ecting 
millions of persons in the world. 
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